Filed
Pursuant to Rule 424b2
Registration No. 333-143867
Title
of each Class of |
Amount
to be |
Proposed |
Proposed |
Amount of Registration |
|
6.40% Senior Notes due 2017 |
$375,000,000 |
100% |
$375,000,000 |
$11,512.50 |
|
6.95% Senior Notes due 2037 |
$425,000,000 |
100% |
$425,000,000 |
$13,047.50 |
|
Guarantees of 6.40% Senior Notes due 2017(2) |
-- |
-- |
-- |
-- |
|
Guarantees of 6.95% Senior Notes due 2037(2) |
-- |
-- |
-- |
-- |
|
Total |
$800,000,000 |
100% |
$800,000,000 |
$24,560.00 |
|
(1) Calculated in accordance with Rule 457(r) under the Securities Act of 1933.
(2) Pursuant to Rule 457(n), no separate fee will be required to be paid in respect of guarantees of our senior debt securities which are being registered concurrently.
PROSPECTUS SUPPLEMENT
(To Prospectus dated June 19, 2007)
$800,000,000
$375,000,000 6.40% Senior Notes due 2017
$425,000,000 6.95% Senior Notes due 2037
Interest payable on July 1 and January 1
We will pay interest on the notes on July 1 and January 1 of each year, beginning January 1, 2008. The 6.40% notes will mature on July 1, 2017. The 6.95% notes will mature on July 1, 2037. We may redeem some or all of the notes of either series at any time at the applicable redemption prices described in this prospectus supplement.
The notes will be senior unsecured obligations of ours and will rank equally with our other existing and future senior unsecured obligations. The notes will be guaranteed by certain of our domestic wholly owned subsidiaries. Each guarantee will be a senior unsecured obligation of the subsidiary guarantor issuing such guarantee and will rank equally with other existing and future senior unsecured obligations of such subsidiary guarantor. The notes will be issued only in registered form in denominations of $2,000 and integral multiples of $1,000.
Investing in the notes involves risks that are described in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2006, incorporated by reference into this prospectus supplement, and in the “Risk Factors” section beginning on page S-8 of this prospectus supplement.
NOTES DUE 2017 – PRICE 99.786% AND ACCRUED INTEREST, IF ANY
NOTES DUE 2037 – PRICE 98.891% AND ACCRUED INTEREST, IF ANY
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
|
|
6.40% Senior |
6.95% Senior |
||||||||||||||||||||||||||
Per Note |
Total |
Per Note |
Total |
|||||||||||||||||||||||||
|
Public offering price(1) |
|
99.786 |
% |
|
|
$ |
|
374,197,500 |
|
98.891 |
% |
|
|
$ |
|
420,286,750 |
||||||||||||
|
Underwriting discount |
|
0.650 |
% |
|
|
$ |
|
2,437,500 |
|
0.875 |
% |
|
|
$ |
|
3,718,750 |
||||||||||||
|
Proceeds, before expenses, to Quest Diagnostics |
|
99.136 |
% |
|
|
$ |
|
371,760,000 |
|
98.016 |
% |
|
|
$ |
|
416,568,000 |
||||||||||||
|
|
||||||||||||||||||||
(1) |
|
Plus accrued interest from June 22, 2007, if settlement occurs after that date.
|
||||||||||||||||||
The Securities and Exchange Commission and state securities regulators have not approved or disapproved these securities, or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The notes will be ready for delivery in book-entry form only through The Depository Trust Company and its participants, including Euroclear and Clearstream Luxembourg, on or about June 22, 2007.
Joint Book-Running Managers
|
|
|
|
|
| MORGAN STANLEY | BANC OF AMERICA SECURITIES LLC |
MERRILL LYNCH & CO. |
||
|
||||
Co-Managers
|
|
|
|
|
| Barclays Capital | JPMorgan |
Wachovia Securities |
||
|
||||
June 19, 2007.
TABLE OF CONTENTS
Page
S-1
S-8
S-11
S-13
S-14
S-15
S-16
S-18
S-21
S-24
S-44
S-48
S-50
S-50
S-50
Page
ii
ii
iii
1
3
4
5 Description of Senior Debt Securities and Guarantees of Senior Debt Securities
6
7
8
8 You should rely only on the information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus. We have not, and the underwriters have not,
authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and the underwriters
are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus supplement, the
accompanying prospectus and the documents incorporated by reference is accurate only as of their respective dates. Our business, financial condition, cash flows, results of operations and prospects
may have changed since these dates. References to “we,” “us,” “our,” “Quest Diagnostics” and the “Company” are to Quest Diagnostics Incorporated and its consolidated subsidiaries unless otherwise specified or the context
otherwise requires. i
This summary highlights selected information appearing elsewhere in this prospectus supplement and may not contain all of the information that is important to you. You should carefully read this
prospectus supplement in its entirety, including the documents incorporated by reference. Our Company We are the nation’s leading provider of diagnostic testing, information and services, providing insights that enable physicians and other healthcare professionals to make decisions to improve
health. We offer patients and physicians the broadest access to diagnostic laboratory services through our nationwide network of laboratories and our own patient service centers. We provide
interpretive consultation through the largest medical and scientific staff in the industry, with approximately 900 M.D.’s and Ph.D.’s around the country. We are the leading provider of esoteric testing,
including gene-based testing, the leading provider of anatomic pathology services, including dermatopathology, and the leading provider of testing for drugs of abuse. We are also a leading provider of
testing for clinical trials and risk assessment services for the life insurance industry. We empower healthcare organizations and clinicians with state-of-the-art information technology solutions that can
improve patient care and medical practice. During 2006, we generated net revenues of $6.3 billion and processed approximately 151 million requisitions for testing. Each requisition form accompanies a patient specimen, indicating the tests
to be performed and the party to be billed for the tests. Our customers include patients, physicians, hospitals, employers, governmental institutions and other commercial clinical laboratories. On May
31, 2007, we acquired AmeriPath Group Holdings, Inc., the ultimate parent of AmeriPath, Inc., which generated net revenues of $752 million during 2006. We operate a nationwide network of greater than 2,100 of our own patient service centers, principal clinical laboratories located in more than 30 major metropolitan areas throughout the United
States and approximately 150 smaller “rapid response” laboratories (including, in each case, facilities operated at our joint ventures). We provide full esoteric testing services, including gene-based
testing, on both coasts through our Quest Diagnostics Nichols Institute laboratory facilities, located in San Juan Capistrano, California and Chantilly, Virginia, and through our Specialty Laboratories
facility located in Valencia, California, as well as infectious and immunologic disease testing through our Focus Diagnostics laboratory facility, located in Cypress, California. Our AmeriPath subsidiary
operates 40 outpatient anatomic pathology laboratories and provides inpatient anatomic pathology and medical director services for approximately 200 hospitals throughout the country. We also have
laboratory facilities in Mexico City, Mexico, San Juan, Puerto Rico and Heston, England. Our principal executive offices are located at 1290 Wall Street West, Lyndhurst, New Jersey 07071, telephone number: (201) 393-5000. The AmeriPath Acquisition On May 31, 2007, we completed the acquisition of AmeriPath Group Holdings, Inc., or AmeriPath, a Delaware corporation. As a result of the merger, AmeriPath is a wholly-owned subsidiary of
ours. Prior to the acquisition, Welsh, Carson, Anderson & Stowe IX, L.P. was the holder of a majority of the outstanding shares of common stock and participating preferred stock of AmeriPath. The aggregate consideration paid in connection with the merger was approximately $2 billion, including the assumption of approximately $780 million of indebtedness (including interest). We
funded the acquisition, as well as the refinancing of certain of our other debt, with borrowings of $1.6 billion under our term loan facility, borrowings of $780 million under our $1.0 billion bridge
loan facility, and from cash on hand. As part of the refinancing of AmeriPath debt, on May 21, 2007, we commenced a tender offer and consent solicitation for the $350 million 101/2% Senior Subordinated Notes of AmeriPath, Inc. S-1
On June 8, 2007, we purchased $348.03 million of such notes pursuant to an early settlement of the tender offer, at which time certain amendments to the indenture governing the notes became
operative. In addition, on May 31, 2007, we called for redemption the $125 million Senior Unsecured Floating Rate PIK Toggle Notes due 2014 of AmeriPath Intermediate Holdings, Inc., the direct parent
of AmeriPath, Inc. and an indirect wholly-owned subsidiary of AmeriPath Group Holdings, Inc., and deposited sufficient funds with the trustee to pay for such notes on the redemption date. As Adjusted Combined Impact of the AmeriPath Acquisition and Related Transactions The following discussion of as adjusted combined financial information reflects the impact of the following transactions, which we refer to in this prospectus supplement as “the Transactions”:
•
our purchase, on May 31, 2007, of AmeriPath, including the all-cash purchase price and related transaction costs associated with the AmeriPath acquisition; • a $1.0 billion bridge loan facility entered into to fund the acquisition of AmeriPath, of which $780 million was drawn after March 31, 2007, and will be refinanced with the proceeds of this
offering; • a new five-year $1.6 billion term loan facility entered into to fund the acquisition of AmeriPath; • the repayment of AmeriPath’s existing debt of approximately $780 million (including interest); • the repayment of the interim credit agreement of $450 million borrowed in connection with the acquisition of POCT Holding AB, or HemoCue; and • the completion of this $800 million offering of senior notes. The acquisition of AmeriPath will be accounted for under the purchase method of accounting. As such, the cost to acquire AmeriPath will be allocated to the respective assets acquired and
liabilities assumed based on their estimated fair values as of the closing date. The as adjusted combined financial information discussion below reflects a preliminary allocation of the cost to acquire
AmeriPath to the assets acquired and liabilities assumed based on preliminary estimates, which are subject to change. Management is in the early stages of assessing the estimated fair values of the
assets acquired and the liabilities assumed. The following as adjusted combined financial information is not pro forma financial information prepared in accordance with Article 11 of Regulation S-X. As of March 31, 2007, our total assets approximated $6.2 billion and total liabilities approximated $3.2 billion. As of March 31, 2007, AmeriPath, Inc.’s total assets and liabilities approximated
$1.4 billion and $0.8 billion, respectively. Assuming the Transactions occurred on March 31, 2007, our unaudited as adjusted combined total assets are estimated to approximate $8.3 billion to $8.8
billion, reflecting a preliminary purchase price allocation of the cost to acquire AmeriPath primarily associated with goodwill and other intangible assets. Assuming the Transactions occurred on March
31, 2007, our unaudited as adjusted combined total liabilities are estimated to approximate $5.3 billion to $5.8 billion, reflecting primarily an increase in debt outstanding. See “Capitalization” for
further details regarding total capitalization on an actual and as adjusted basis to reflect the impact of the Transactions. For the three months ended March 31, 2007 and year ended December 31, 2006, our income from continuing operations was $108 million and $626 million, respectively. For the three months
ended March 31, 2007 and year ended December 31, 2006, AmeriPath, Inc.’s net income was $0.2 million and $10.5 million, respectively. Assuming the Transactions occurred January 1, 2006, as
adjusted combined income from continuing operations for the three months ended March 31, 2007 and the year ended December 31, 2006 are estimated to approximate $90 million and $567 million,
respectively, reflecting primarily an increase in as adjusted combined interest expense as a result of the Transactions and excluding any net synergies anticipated from the AmeriPath acquisition. S-2
The Offering The following is a brief summary of some of the terms of this offering. For a more complete description of the terms of the notes, see “Description of Notes” in this prospectus supplement.
Issuer
Quest Diagnostics Incorporated.
Notes offered
$375,000,000 aggregate principal amount of 6.40% senior notes due 2017.
$425,000,000 aggregate principal amount of 6.95% senior notes due 2037.
Maturities
6.40% senior notes due 2017: July 1, 2017.
6.95% senior notes due 2037: July 1, 2037.
Interest payment dates
July 1 and January 1, beginning January 1, 2008.
Guarantees
The notes will be fully and unconditionally guaranteed, jointly and severally, by certain of our domestic wholly owned subsidiaries.
Ranking
The notes will be senior unsecured obligations of ours and will rank equally with our other existing and future senior unsecured obligations. Each
guarantee will be a senior unsecured obligation of the subsidiary guarantor issuing such guarantee and will rank equally with other existing and future
senior unsecured obligations of such subsidiary guarantor. The notes and the guarantees will effectively rank junior to all liabilities of our subsidiaries that
are not guarantors. The notes and the guarantees will also effectively be subordinated to any existing and future secured obligations of ours or our
subsidiary guarantors as to the assets securing such obligations.
As of March 31, 2007, after giving effect to the Transactions:
•
we and our subsidiary guarantors would have had total debt outstanding of $3.64 billion, of which $5.5 million is secured; and
•
our subsidiaries that are not guarantors (other than certain subsidiaries which will guarantee our term loans, our senior unsecured revolving credit
facility and existing senior notes) would have had debt outstanding of $314 million, of which $300 million was incurred under our secured receivables
credit facility.
For more information, see “Description of Certain Other Indebtedness,” “Capitalization” and “Description of Notes.”
Optional redemption
We may redeem some or all of the notes of either series, at any time, at the applicable redemption prices described in this prospectus supplement. For a
more detailed description, see “Description of Notes—Optional Redemption.” S-3
Repurchase Upon a Change of Control
Upon the occurrence of a Change of Control Triggering Event (as defined in this prospectus supplement), we will be required to make an offer to
purchase the notes at a price equal to 101% of their principal amount plus accrued and unpaid interest to the date of repurchase. See “Description of
Notes—Change of Control.”
Covenants
The indenture governing the notes will contain covenants that, among other things, will limit our ability and the ability of our subsidiary guarantors to:
•
create certain liens;
•
enter into certain sale and leaseback transactions;
•
make payments to certain non-guarantor subsidiaries;
•
consolidate, merge or transfer all or substantially all of our assets and the assets of our subsidiaries on a consolidated basis; and
•
incur indebtedness of non-guarantor subsidiaries.
These covenants are subject to important exceptions and qualifications, which are described in this prospectus supplement. For a more detailed
description, see “Description of Notes.”
Use of proceeds
We estimate that the net proceeds from this offering of notes after deducting underwriting discounts but before deducting other expenses of the offering
will be approximately $788.3 million. We intend to use these proceeds, together with cash on hand, to repay all borrowings under the bridge loan facility
incurred to pay a portion of the purchase price and transaction expenses of the AmeriPath acquisition and to refinance the debt of AmeriPath. See “Use
of Proceeds” and “Summary—The AmeriPath Acquisition.”
Risk factors
See “Risk Factors” and the other information in this prospectus supplement and in our Annual Report on Form 10-K for the fiscal year ended December
31, 2006, incorporated by reference into this prospectus supplement for a discussion of factors you should carefully consider before deciding to invest in
the notes. S-4
Summary Selected Historical Financial Data of Quest Diagnostics
Three Months Ended
Year Ended December 31,
2007 (a)
2006
2006 (b)
2005 (g)
2004
(in thousands, except for ratios) Operations Data: Net revenues
$
1,526,208
$
1,553,105
$
6,268,659
$
5,456,726
$
5,066,986 Operating income
200,870
258,718
(e)
1,128,077
(c),(e)
1,007,548
(h)
880,854
(i) Income from continuing operations
107,515
154,603
(d)
625,692
(d)
573,196
(j)
492,415
(k) (Loss)/income from discontinued operations
(1,622
)
(9,967
)
(39,271
)(f)
(26,919
)(f)
6,780 Net income
105,893
144,636
586,421
546,277
499,195 Balance Sheet Data (at end of period): Cash and cash equivalents
$
158,397
$
156,461
$
149,640
$
92,130
$
73,302 Accounts receivable, net
810,576
775,724
774,414
732,907
649,281 Total assets
6,186,542
5,434,568
5,661,482
5,306,115
4,203,788 Long-term debt
1,238,265
1,240,501
1,239,105
1,255,386
724,021 Total debt
2,005,306
1,532,390
1,555,979
1,592,225
1,098,822 Total stockholders’ equity
3,029,232
2,865,296
3,019,171
2,762,984
2,288,651 Other Data: Net cash provided by operating activities
$
151,553
$
240,659
$
951,896
$
851,583
$
798,780 Net cash (used) in investing activities
(345,947
)
(27,991
)
(414,402
)
(1,079,793
)
(173,700
) Net cash (used in) provided by financing activities
(203,151
)
(148,337
)
(479,984
)
247,038
(706,736
) Provision for doubtful accounts
67,508
63,423
243,443
233,628
226,310 Rent expense
40,183
38,722
153,185
139,660
132,883 Capital expenditures
40,126
42,186
193,422
224,270
176,125 Depreciation and amortization
50,335
49,060
197,398
176,124
168,726 Ratio of earnings to fixed charges
5.4x
—
8.2x
9.9x
9.2x
(a)
On January 31, 2007, we completed the acquisition of HemoCue, which generated annualized revenues of approximately $90 million. Consolidated operating results for 2007 include the results of
operations of HemoCue subsequent to the closing of the acquisition. (b) On July 3, 2006, we completed the acquisition of Focus Technologies Holding Company, or Focus Diagnostics, which generated annualized revenues of approximately $65 million. Consolidated
operating results for 2006 include the results of operations of Focus Diagnostics subsequent to the closing of the acquisition. See Note 3 to the Consolidated Financial Statements included in our
Annual Report on Form 10-K for the year ended December 31, 2006, which is incorporated by reference into this prospectus supplement. (c) During 2006, we recorded $55 million of stock-based compensation expense in accordance with Statement of Financial Accounting Standards, or SFAS, No. 123, revised 2004, “Share-Based
Payment,” or SFAS 123R. (d) During 2006, we recorded $10 million related to net investment losses, which included a $15.8 million gain on the sale of an investment recorded during the first quarter of 2006. S-5
March 31,
(e) During 2006, we recorded $23 million in charges as a result of finalizing our plan of integration of LabOne, Inc., or LabOne, and $4.1 million in charges related to consolidating operations in
California into a new facility. (f) During 2006, we recorded $32 million in charges as a result of discontinuing the operations of NID, a test kit manufacturing subsidiary. During the fourth quarter of 2005, we recorded a $16
million charge to write-off certain assets in connection with a product hold at NID. (g) On November 1, 2005, we completed the acquisition of LabOne, which had annual revenues of approximately $468 million. Consolidated operating results for 2005 include the results of
operations of LabOne subsequent to the closing of the acquisition. See Note 3 to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended
December 31, 2006, which is incorporated by reference into this prospectus supplement. (h) During 2005, we recorded a $6.2 million charge primarily related to forgiveness of amounts owed by patients and physicians, and related property damage as a result of hurricanes in the Gulf
Coast. (i) During 2004, we recorded a $10.3 million charge associated with the acceleration of certain pension obligations in connection with the succession of our prior Chief Executive Officer. (j) During 2005, we recorded a $7.1 million charge associated with the write-down of an investment. (k) During 2004, we recorded a $2.9 million charge to interest expense, net representing the write-off of deferred financing costs associated with the refinancing of our bank debt and credit facility. S-6
Summary Selected Historical Financial Data of AmeriPath, Inc.(a)
Three Months Ended
Year Ended December 31,
2007
2006
2006(c)
2005
2004
(in thousands) Operations Data: Net revenues
$
200,694
$
170,936
$
752,321
$
563,617
$
507,271 Operating income
15,072
14,569
79,877
65,931
49,789 Net income (loss)
219
(2,090
)
10,527
9,921
1,514 Balance Sheet Data (at end of period): Cash and cash equivalents (b)
$
—
$
8,648
$
182
$
3,998
$
20,980 Accounts receivable, net
153,279
122,122
137,947
84,968
76,567 Total assets
1,437,234
1,340,786
1,411,101
984,149
964,309 Long-term debt, including current portion
625,534
610,826
624,259
479,490
497,853 Total stockholders’ equity
629,932
565,563
606,340
384,717
358,092 Other Data: Net cash (used in) provided by operating activities
$
(9,595
)
$
394
$
30,624
$
38,152
$
54,038 Net cash used in investing activities
(14,079
)
(185,127
)
(262,672
)
(52,740
)
(70,808
) Net cash provided by (used in) financing activities
23,492
189,383
228,232
(2,394
)
14,214 Provision for doubtful accounts
19,358
19,840
84,936
73,766
76,463 Rent expense
4,198
2,432
13,911
9,624
7,634 Capital expenditures
14,004
13,475
57,334
29,431
12,803 Depreciation and amortization (d)
8,906
7,951
34,933
24,934
22,774
(a)
This presentation is for AmeriPath, Inc. We acquired AmeriPath Group Holdings, Inc., the ultimate parent of AmeriPath, Inc., whose principal assets consisted of cash (which was used to repay
debt) and its indirect investment in AmeriPath, Inc., and whose principal liabilities consisted of debt, which was repaid in connection with the acquisition of AmeriPath Group Holdings, Inc. As
of the date hereof, AmeriPath Group Holdings, Inc. has no significant assets other than its indirect investment in AmeriPath, Inc. (b) Cash and cash equivalents exclude restricted cash which consists of premium revenue received by AmeriPath, Inc.’s insurance captive to be used for future insurance claims and expenses. (c) On January 31, 2006, AmeriPath, Inc. completed its acquisition of Specialty Laboratories, Inc., or Specialty, which generated net revenues in 2005 of approximately $150 million. Consolidated
operating results for 2006 include the results of operations of Specialty subsequent to the closing of the acquisition. (d) Three months ended March 31, 2007 and 2006 exclude amortization of deferred debt costs of $0.7 million and $0.6 million, respectively, as these costs were included in interest expense. S-7
March 31,
You should carefully consider the risks described below and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2006, incorporated by reference into this prospectus
supplement, before making a decision to invest in our notes. Some of the following factors relate principally to our business and the industry in which we operate. Other factors relate principally to your
investment in the notes. The risks and uncertainties described below are not the only ones facing our company. Additional risks and uncertainties not presently known to us or that we currently deem
immaterial may also materially adversely affect our business and operations. If any of the matters included in the following risks were to occur, our business, financial condition, results of operations, cash flows or prospects could be materially adversely affected. In such case,
you may lose all or part of your original investment. On May 31, 2007, we completed the acquisition of AmeriPath. As a result of the merger, AmeriPath is a wholly-owned subsidiary of ours. The aggregate consideration paid in connection with
the merger was approximately $2 billion, including the assumption of approximately $780 million of indebtedness (including interest). The acquisition involves the integration of a separate company that previously operated independently and has different systems, processes and cultures. The process of combining AmeriPath with
our operations may be disruptive to both of our businesses and may cause an interruption of, or a loss of momentum in, such businesses as a result of the following difficulties, among others:
•
loss of key customers or employees; • failure to maintain the quality of services that our company has historically provided; • diversion of management’s attention from the day-to-day business of our company as a result of the need to deal with the foregoing disruptions and difficulties; and • the added costs of dealing with such disruptions. In addition, during this integration AmeriPath expects to complete the development and implementation of a new laboratory information system and billing information system to be used by all
of AmeriPath’s laboratories. Failure to properly implement the new information systems could cause disruptions in service and present significant conversion risks. Even if we are able to successfully complete the integration of the operations of AmeriPath, we may not be able to realize all or any of the benefits that we expect to result from such
integration. Because most of our clinical laboratory testing is performed under arrangements that are terminable at will or on short notice, any interruption of or deterioration in our services may result in a
customer’s decision to stop using us for clinical laboratory testing. We cannot assure you that we will be able to retain key technical and management personnel or that we will realize the anticipated
benefits of the AmeriPath acquisition, either at all or in a timely manner. As part of our growth strategy, we may in the future acquire additional clinical laboratories or other healthcare-related
businesses. Our outstanding debt may impair our financial and operating flexibility. As of March 31, 2007, after giving effect to the Transactions as if they occurred on that date, we would have had approximately $3.95 billion of debt outstanding, with $750 million of available
capacity under our senior unsecured revolving credit facility. Except for outstanding letters of credit, bank guarantees and operating leases, we do not have any off-balance sheet financing
arrangements in place or available. See Note 10 to our Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2006 and Note 5 to our Consolidated
Financial Statements in our quarterly report on Form 10-Q for the quarter ended March 31, 2007 for further details related to our outstanding debt. Set forth in the table below, for each of the next
five years, is the aggregate amount of scheduled principal, estimated interest and total payments related to our S-8
outstanding debt as of March 31, 2007, after giving effect to the Transactions as if they had occurred on that date, including capital leases, assuming that maturing debt is refinanced for purposes of
estimating interest.
Twelve Months
Principal
Interest
Total
(in thousands) 2007
$
357,041
$
178,009
$
535,050 2008
142,091
209,242
351,333 2009
122,055
210,573
332,628 2010
560,246
201,853
762,099 2011
915,258
228,639
1,143,897 Our debt portfolio is sensitive to changes in interest rates. As of March 31, 2007, after giving effect to the Transactions, we would have had approximately $1.97 billion of floating rate debt.
Based on our net exposure to interest rate changes, an assumed 10% change in interest rates on our variable rate indebtedness (representing approximately 54 basis points) would impact annual net
interest expense by approximately $10.6 million, assuming no changes to the debt outstanding at March 31, 2007. In addition, any future borrowings by us under the unsecured revolving credit facility,
the secured receivables credit facility or the issuance of other floating rate debt will expose us to additional interest rate risk. Interest rates on our senior unsecured revolving credit facility, term loans
and secured receivables credit facility are also subject to a pricing schedule that fluctuates based on changes in our credit rating. Our debt agreements contain various restrictive covenants. These restrictions could limit our ability to use operating cash flow in other areas of our business because we must use a portion of
these funds to make principal and interest payments on our debt. We have obtained ratings on our debt from Standard and Poor’s Ratings Services and Moody’s Investors Service. There can be no assurance that any rating so assigned will remain for any given
period of time or that a rating will not be lowered or withdrawn entirely by a rating agency if in that rating agency’s judgment future circumstances relating to the basis of the rating, such as adverse
changes in our company or our industry, so warrant. If such ratings are lowered, the borrowing costs on our senior unsecured revolving credit facility, secured receivables facility and term loans would
increase. Changes in our credit ratings do not require repayment or acceleration of any of our debt. We, or our subsidiaries, may incur additional indebtedness in the future. The notes offered hereby do not limit our or our subsidiaries’ ability to incur indebtedness. Our ability to make principal
and interest payments will depend on our ability to generate cash in the future. If additional debt is added to our current debt, a greater portion of our cash flows will be needed to satisfy our debt
service obligations; and if we do not generate sufficient cash to meet our debt service requirements, we may need to seek additional financing. In this case, it may be more difficult, or we may be
unable, to obtain financing on terms that are acceptable to us. As a result, we would be more vulnerable to general adverse economic, industry and capital markets conditions as well as the other
risks associated with indebtedness. Our obligations under the notes are guaranteed by our subsidiaries to the extent described in this prospectus supplement. These guarantees are subject to various federal and state fraudulent
conveyance laws enacted for the protection of creditors. The issuance of a guarantee by any of our subsidiaries will constitute a fraudulent conveyance if:
•
the guarantee was incurred by the subsidiary with the intent to hinder, delay or defraud any present or future creditor; or • the subsidiary did not receive fair consideration for issuing the guarantee and such subsidiary (1) was insolvent or rendered insolvent by reason of the issuance of the guarantee, (2) was engaged
or about to engage in a business or transaction for which the remaining assets of the subsidiary constituted unreasonably small capital to carry on its business or (3) intended to incur debts
beyond its ability to pay such debts as they matured. S-9
Ended December 31,
Generally, an entity will be considered insolvent if:
•
the sum of its debts is greater than the fair value of its property; • the present fair value of its assets is less than the amount that it will be required to pay on its existing debts as they become due; or • it cannot pay its debts as they become due. If a court finds a guarantee issued by a subsidiary of ours to constitute a fraudulent conveyance, the court could give a lower priority to, or subordinate, the claims of the notes against this
subsidiary to the claims of other creditors of this subsidiary. In addition, a court could void all or part of the guarantee. To the extent the guarantee issued by a subsidiary of ours was voided as a
fraudulent conveyance, the holders of our notes guaranteed by our subsidiary guarantors would cease to have any claim against the subsidiary and would be creditors solely of Quest Diagnostics and
any other subsidiary guarantor that was not found to have made a fraudulent conveyance. Furthermore, a court may be more likely to find that guarantees issued by subsidiaries after the date the
notes are issued constitute a fraudulent conveyance. See “Description of Notes—Guarantees.” The notes and the guarantees are senior unsecured obligations and therefore will be effectively subordinated to any of our or our subsidiary guarantors’ secured obligations to the extent of the
value of the assets securing such obligations. The indenture does not limit the amount of indebtedness that we and any of our subsidiary guarantors can incur, but does limit the amount of
indebtedness our non-guarantor subsidiaries are permitted to incur (as described below). In addition, the indenture limits the amount of secured indebtedness pursuant to the covenant described under
the heading “Description of Notes—Limitation on Liens.” This covenant is subject to important exceptions described under such heading. As of March 31, 2007, after giving effect to the Transactions,
we and our subsidiary guarantors would have had outstanding $5.5 million of secured debt. We conduct our operations through subsidiaries, which generate a substantial portion of our operating income and cash flow. As a result, distributions or advances from our subsidiaries are a
major source of funds necessary to meet our debt service and other obligations. Contractual provisions, laws or regulations, as well as any subsidiary’s condition and operating requirements, may limit
our ability to obtain cash required to pay our debt service and other obligations. The notes will be structurally subordinated to all existing and future obligations of our subsidiaries (unless such
subsidiaries are subsidiary guarantors), including claims with respect to trade payables. In addition, the guarantees of our subsidiary guarantors will be structurally subordinated to all existing and
future obligations of any subsidiary or Quest Diagnostics or a subsidiary guarantor (unless such subsidiaries are also subsidiary guarantors), including claims with respect to trade payables. This means
that holders of our notes as guaranteed by our subsidiary guarantors will have a junior position with respect to such obligations of our direct and indirect subsidiaries that are not subsidiary
guarantors on the assets and earnings of such subsidiaries. Except as disclosed in the next sentence, as of March 31, 2007, after giving effect to the Transactions our subsidiaries that are not
guarantors would have had debt outstanding of $314 million, of which $300 million was incurred under our secured receivables credit facility. Certain AmeriPath subsidiaries and our MedPlus, Inc.
subsidiary (which has approximately $65 million in assets) will not be guarantors of the notes, but will guarantee certain of our other indebtedness, including our term loans, our senior unsecured
revolving credit facility and existing senior notes. Our non-guarantor subsidiaries are limited in the amount of indebtedness they are permitted to incur pursuant to the covenant described under “Description of Notes—Limitation on Subsidiary
Indebtedness and Preferred Stock.” This covenant is subject to important exceptions described under such heading. In addition, the guarantees of our subsidiary guarantors may be released in certain
circumstances, which are described under the heading “Description of Notes—Guarantees” or may be avoided or subordinated in favor of the subsidiary guarantors’ other creditors as described in this
prospectus supplement under the heading “Risk Factors—Federal and state laws permit a court to void a guarantee issued by any of our subsidiaries if the court finds the guarantee to constitute a
fraudulent conveyance.” S-10
Some statements and disclosures in this prospectus supplement, or any accompanying prospectus and the documents incorporated herein or therein by reference are forward-looking statements.
Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could
significantly cause our plans and expectations, including actual results, to differ materially from the forward-looking statements. The Private Securities Litigation Reform Act of 1995, or the Litigation
Reform Act, provides a “safe harbor” for forward-looking statements to encourage companies to provide prospective information about their companies without fear of litigation. We would like to take advantage of the “safe harbor” provisions of the Litigation Reform Act in connection with the forward-looking statements included, or incorporated by reference, in this
document. Investors are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented, or incorporated by reference, in this document. The following
important factors could cause our actual financial results to differ materially from those projected, forecasted or estimated by us in forward-looking statements: (a) Heightened competition, including increased pricing pressure, competition from hospitals, and competition from physicians. (b) Impact of changes in payer mix, including any shift from fee-for-service to capitated fee arrangements. (c) Adverse actions by government or other third-party payers, including unilateral reduction of fee schedules payable to us, competitive bidding, an increase in the practice of negotiating for
exclusive arrangements that involve aggressively priced capitated or fee for service payments by healthcare insurers or other payers and threats by third-party payers against physicians and patients
that effectively eliminate their choice to use an out-of-network provider under preferred provider organization and similar plans. (d) The impact upon our testing volume and collected revenue or general or administrative expenses resulting from our compliance with Medicare and Medicaid administrative policies and
requirements of third-party payers. These include: (1) the requirements of Medicare carriers to provide diagnosis codes for many commonly ordered tests and the possibility that third-party payers will increasingly adopt similar requirements; (2) the policy of the Centers for Medicare and Medicaid Services to limit Medicare reimbursement for tests contained in automated chemistry panels to the amount that would have been
paid if only the covered tests, determined on the basis of demonstrable “medical necessity,” had been ordered; (3) continued inconsistent practices among the different local carriers administering Medicare; (4) inability to obtain from patients an advance beneficiary notice form for tests that cannot be billed without prior receipt of the form; (5) the potential need to monitor charges and lower certain fees to Medicare to comply with the Office of the Inspector General’s proposed rule pertaining to exclusion of providers for
submitting claims to Medicare containing charges that are substantially in excess of the provider’s usual charges; and (6) increased challenges in operating as a non-contracted provider with respect to healthcare insurers. (e) Adverse results from pending or future government investigations, lawsuits or private actions. These include, in particular, significant monetary damages, loss or suspension of licenses, and/or
suspension or exclusion from the Medicare and Medicaid programs and/or criminal penalties. S-11
(f) Failure to efficiently integrate acquired businesses and to manage the costs related to any such integration, or to retain key technical, medical and management personnel. (g) Inability to obtain professional liability or other insurance coverage or a material increase in premiums for such coverage or reserves for self-insurance. (h) Denial of certification under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, or denial of other licenses for any of our clinical laboratories under the CLIA standards,
revocation or suspension of the right to bill the Medicare and Medicaid programs or other adverse regulatory actions by federal, state and local agencies. (i) Changes in federal, state or local laws or regulations, including changes that result in new or increased federal or state regulation of commercial clinical laboratories, including regulation by
the Food and Drug Administration. (j) Inability to achieve expected benefits from our acquisitions of other businesses. (k) Inability to achieve additional benefits from our Six Sigma and standardization initiatives. (l) Adverse publicity and news coverage about the clinical laboratory industry or us. (m) Computer or other IT system failures that affect our ability to perform tests, report test results or properly bill customers, including potential failures resulting from the standardization of our
IT systems and other system conversions, telecommunications failures, malicious human acts (such as electronic break-ins or computer viruses) or natural disasters. (n) Development of technologies that substantially alter the practice of laboratory medicine, including technology changes that lead to the development of more cost-effective tests such as (1)
point-of-care tests that can be performed by physicians in their offices, (2) esoteric tests that can be performed by hospitals in their own laboratories or (3) home testing that can be carried out
without requiring the services of clinical laboratories. (o) Issuance of patents or other property rights to our competitors or others that could prevent, limit or interfere with our ability to develop, perform or sell our tests or operate our business. (p) Development of tests by our competitors or others which we may not be able to license, or usage of our technology or similar technologies or our trade secrets by competitors, any of which
could negatively affect our competitive position. (q) Regulatory delay or inability to commercialize newly licensed tests or technologies or to obtain appropriate reimbursements for such tests. (r) Inability to obtain or maintain adequate patent and other proprietary rights protections of our products and services or to successfully enforce our proprietary rights. (s) Impact of any national healthcare information network and the adoption of standards for health information technology interoperability that are incompatible with existing software and
hardware infrastructure requiring widespread replacement of systems and/or software. (t) The impact of the privacy regulations, security regulations and standards for electronic transactions regulations issued under the Health Insurance Portability and Accountability Act of 1996
and any applicable state laws or regulations. (u) Inability to promptly or properly bill for our services or to obtain appropriate payments for services that we do bill. (v) Changes in interest rates and changes in our credit ratings from Standard & Poor’s Rating Services and Moody’s Investor Services causing an unfavorable impact on our cost of and access to
capital. (w) Inability to hire and retain qualified personnel or the loss of the services of one or more of our key senior management personnel. (x) Terrorist and other criminal activities, hurricanes, earthquakes or other natural disasters, which could affect our customers, transportation or systems, or our facilities, and for which insurance
may not adequately reimburse us. S-12
RATIO OF EARNINGS TO FIXED CHARGES Set forth below is information concerning the historical ratio of earnings to fixed charges for Quest Diagnostics. This ratio shows the extent to which our business generates enough earnings after
the payment of all expenses other than interest to make required interest payments on our debt. For this purpose, earnings consist of pretax income from continuing operations plus fixed charges. Fixed charges consist of interest expense and one-third of rental expense, representing that
portion of rental expense we deemed representative of an appropriate interest factor.
Three Months
Year Ended December 31,
2007
2006
2005
2004
2003
2002 Ratio of earnings to fixed charges
5.4x
8.2x
9.9x
9.2x
8.4x
7.2x S-13
Ended March 31,
We estimate that the net proceeds from this offering of notes after deducting underwriting discounts but before deducting other expenses of the offering will be approximately $788.3 million. We
intend to use these proceeds, together with cash on hand to repay all borrowings under the bridge loan facility incurred to pay a portion of the purchase price and transaction expenses of the
AmeriPath acquisition and to refinance the debt of AmeriPath. The amount drawn on the bridge loan facility was $780 million. The interest rate on the bridge loan facility was 5.72% as of May 31,
2007. The facility matures on May 30, 2008. See “Summary—The AmeriPath Acquisition” and “Description of Certain Other Indebtedness—Bridge Loan.” S-14
The following table sets forth our cash and cash equivalents, debt, and total capitalization at March 31, 2007 on an actual basis and as adjusted to reflect the following transactions, or the
Transactions, as if they had occurred on that date:
•
our purchase, on May 31, 2007, of AmeriPath, including the all-cash purchase price and related transaction costs associated with the AmeriPath acquisition; • a $1.0 billion bridge loan facility entered into to fund the acquisition of AmeriPath, of which $780 million was drawn after March 31, 2007, and will be refinanced with the proceeds of this
offering; • a new five-year $1.6 billion term loan facility entered into to fund the acquisition of AmeriPath; • the repayment of AmeriPath’s existing debt of approximately $780 million (including interest); • the repayment of the interim credit agreement of $450 million borrowed in connection with the acquisition of POCT Holding AB, or HemoCue; and • the completion of this $800 million offering of senior notes. This table should be read in conjunction with our consolidated financial statements and the related notes and the consolidated financial statements and related notes of AmeriPath, Inc.
incorporated by reference into this prospectus supplement. This table does not reflect a new $750 million senior unsecured revolving credit facility, which replaced our prior $500 million senior
unsecured revolving credit facility in May 2007. Nothing was outstanding under this revolving credit facility on March 31, 2007.
March 31, 2007
Actual
As Adjusted
(in thousands) Cash and cash equivalents
$
158,397
$
38,446
(a) Debt (including current maturities): Short-term borrowings under receivables financing
$
300,000
$
300,000 HemoCue interim credit agreement
450,000
— AmeriPath interim credit agreement
—
— Term loan due 2008
60,000
60,000 Term loan due 2012
—
1,600,000 7.5% Senior notes due 2011
274,530
274,530 5.125% Senior notes due 2010
399,461
399,461 5.45% Senior notes due 2015
498,627
498,627 31/2% Convertible notes due 2034
2,971
2,971 Industrial revenue bonds due 2009
5,378
5,378 Senior notes offered hereby (b)
—
794,484 Other
14,340
14,408 Total debt
2,005,307
3,949,859 Stockholders’ equity
3,029,232
3,029,232 Total capitalization
$
5,034,539
$
6,979,091
(a)
Cash and cash equivalents as adjusted include the assumption of AmeriPath’s cash balances of $26.6 million as of March 31, 2007, (adjusted to exclude $74 million of cash and cash equivalents
used to repay amounts outstanding under AmeriPath, Inc.’s revolving credit facility subsequent to March 31, 2007). Cash and cash equivalents also exclude restricted cash of approximately $30
million. (b) Consists of $375 million 6.40% senior notes due 2017 and $425 million 6.95% senior notes due 2037. S-15
DESCRIPTION OF CERTAIN OTHER INDEBTEDNESS Letter of Credit Lines We have two lines of credit with two financial institutions totaling $85 million for the issuance of letters of credit. The letter of credit lines mature in December 2007, are guaranteed by the
subsidiary guarantors and are expected to be renewed. As of March 31, 2007, there were $62.3 million of outstanding letters of credit under the letter of credit lines. In addition, at March 31, 2007,
AmeriPath had $12.1 million of outstanding letters of credit. Secured Receivables Credit Facility In May 2007, Quest Diagnostics Receivables Inc., a wholly owned subsidiary of ours, increased its existing receivables securitization facility from $300 million to $375 million. The facility matures
on May 23, 2008. The secured receivables credit facility is supported by one-year back-up facilities provided by two banks on a committed basis. Interest on the secured receivables credit facility is
based on rates that are intended to approximate commercial paper rates for highly rated issuers. Borrowings outstanding under the secured receivables credit facility, if any, are classified as a current
liability on our consolidated balance sheet. The borrower under the secured receivables credit facility is not a guarantor of the notes offered hereby. Term Loans and Revolving Credit Facility In December 2003, we entered into a $75 million amortizing term loan due December 2008. Interest is based on LIBOR plus an applicable margin that can fluctuate over a range of up to 119
basis points, based on changes in our public debt ratings. Currently, our borrowing rate for LIBOR-based loans is LIBOR plus 0.50%. The term loan due December 2008 requires principal
repayments of the initial amount borrowed equal to 20% on each of the third and fourth anniversary dates of the funding and the remainder of the outstanding balance on December 31, 2008. As of
May 31, 2007, the interest rate was 5.82%. The term loan due December 2008 is guaranteed by the Subsidiary Guarantors and the Specified Subsidiaries (as such terms are defined in the “Description
of Notes”). In May 2007, we entered into a $1.6 billion term loan facility and a $750 million senior unsecured revolving credit facility which matures in May 2012. The term loan requires principal
repayments of 1.25% of the amount borrowed on the last day of each calendar quarter starting on September 30, 2007, with the quarterly payments increasing on September 30, 2009 to 2.5% of the
amount borrowed and on September 30, 2011 to 17.5% of the amount borrowed, with the remainder of the outstanding balance due on May 31, 2012. Interest under each facility is based on certain
published rates plus an applicable margin that will vary over a range from 40 basis points to 125 basis points based on changes in our public debt ratings. At our option, we may elect to enter into
LIBOR-based interest rate contracts for periods up to six months. Interest on any outstanding amounts not covered under the LIBOR-based interest rate contracts is based on an alternate base rate,
which is calculated by reference to the prime rate or federal funds rate. As of May 31, 2007, the interest rate was 5.72%. The term loan and the senior unsecured revolving credit facility are
guaranteed by the Subsidiary Guarantors and the Specified Subsidiaries (as such terms are defined in the “Description of Notes”). Bridge Loan In May 2007, we entered into a $1 billion bridge loan facility, of which $780 million was drawn to fund the acquisition of AmeriPath. We intend to use the proceeds from this offering to repay
all borrowings under the bridge loan facility. The loan under the bridge credit agreement is due on May 30, 2008. Interest is based on certain published rates plus an applicable margin that will vary
over a range from 40 basis points to 125 basis points based on changes in our public debt ratings. At our option, we may elect to enter into LIBOR-based interest rate contracts for periods up to six
months. Interest on any outstanding amounts not covered under the LIBOR-based interest rate S-16
contracts is based on an alternate base rate, which is calculated by reference to the prime rate or federal funds rate. As of May 31, 2007, the interest rate was 5.72%. Senior Notes We completed a $550 million senior notes offering in June 2001, of which a tranche of $275 million matured in July 2006. The other tranche of $275 million aggregate principal amount of 7.5%
senior notes due 2011 was issued at a discount of approximately $1.1 million. After considering the discount, the effective interest rate on the senior notes due 2011 is 7.6%. The senior notes require
semiannual interest payments which commenced January 12, 2002. We completed a $900 million senior notes offering in October 2005. The notes were issued in two tranches: (a) $400 million aggregate principal amount of 5.125% senior notes due November 1,
2010 issued at a discount of approximately $0.8 million and (b) $500 million aggregate principal amount of 5.45% senior notes due November 1, 2015, issued at a discount of approximately $1.6
million. After considering the discounts, the effective interest rates on the senior notes due 2010 and the senior notes due 2015 are approximately 5.3% and 5.6%, respectively. The senior notes
require semiannual interest payments, which commenced on May 1, 2006. The senior notes are unsecured obligations of ours and rank equally with our other unsecured senior obligations. The senior
notes are guaranteed by the Subsidiary Guarantors and the Specified Subsidiaries (as such terms are defined in the “Description of Notes”). Each guarantee is a senior unsecured obligation of the
subsidiary guarantor issuing such guarantee and ranks equally with other existing and future senior unsecured obligations of such subsidiary guarantor. The covenants and events of default under the
senior notes are substantially the same as the senior notes offered hereby except that such indebtedness does not contain a change of control redemption right for the holders and the senior notes
offered hereby contain a limitation on restricted payments to certain non-guarantor subsidiaries and permit these subsidiaries to guarantee certain debt. S-17
SELECTED HISTORICAL FINANCIAL DATA FOR QUEST DIAGNOSTICS The following table summarizes our selected historical financial data of our company and our subsidiaries at the dates and for each of the periods presented. We derived the selected historical
financial data for the years 2002 through 2006 from our audited consolidated financial statements. We derived the selected historical financial data for the three months ended March 31, 2007 and
2006 from our unaudited interim consolidated financial statements. The unaudited interim consolidated financial statements reflect all adjustments which, in our opinion, are necessary for a fair
statement of the financial condition and results of operations as of and for the periods presented. The unaudited interim consolidated financial statements have been compiled without audit and are
subject to year-end adjustments. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full year. In September 2004, the Emerging Issues Task
Force reached a final consensus on Issue 04-8, “The Effect of Contingently Convertible Instruments on Diluted Earnings per Share,” or Issue 04-8, effective December 31, 2004. Pursuant to Issue 04-
8, we included the dilutive effect of our 13/4% contingent convertible debentures issued November 26, 2001 in our dilutive earnings per common share calculations using the if-converted method,
regardless of whether or not the holders of these securities were permitted to exercise their conversion rights, and retroactively restated previously reported diluted earnings per common share. Effective January 1, 2006, we adopted SFAS 123R using the modified prospective approach and therefore we have not restated results for prior periods. Under this approach, equity awards that
are granted, modified or settled after January 1, 2006 will be measured and accounted for in accordance with SFAS 123R. Unvested awards that were granted prior to January 1, 2006 will continue to
be accounted for in accordance SFAS No. 123, “Accounting for Stock-Based Compensation,” as amended by SFAS No. 148, “Accounting for Stock-Based Compensation-Transition and Disclosure—an
amendment to SFAS No. 123,” except that compensation cost will be recognized in our results of operations. During the third quarter of 2006, we completed our wind down of NID, a test kit
manufacturing subsidiary, and classified the operations of NID as discontinued operations. The selected historical financial data presented below has been restated to report the results of NID as
discontinued operations for all periods presented. The selected historical financial data is only a summary and should be read together with our audited consolidated financial statements and related notes and management’s discussion and
analysis of financial condition and results of operations included in our quarterly reports on Form 10-Q for the three months ended March 31, 2007 and 2006 and our Annual Report on Form 10-K
for the year ended December 31, 2006, incorporated by reference in this prospectus supplement.
Three Months Ended
Year Ended December 31,
2007(a)
2006
2006 (b)
2005 (g)
2004
2003 (h)
2002 (i)
(in thousands, except for per share data) Operations Data: Net revenues
$
1,526,208
$
1,553,105
$
6,268,659
$
5,456,726
$
5,066,986
$
4,686,030
$
4,065,426 Operating income
200,870
258,718
(e)
1,128,077
(c),(e)
1,007,548
(j)
880,854
(k)
784,691
584,316 Income from continuing operations
107,515
154,603
(d)
625,692
(d)
573,196
(l)
492,415
(m)
429,173
317,445 (Loss)/income from discontinued operations
(1,622
)
(9,967
)
(39,271
)(f)
(26,919
)(f)
6,780
7,544
4,708 Net income
105,893
144,636
586,421
546,277
499,195
436,717
322,154 Earnings per common share—basic: (n) Income from continuing operations
$
0.56
$
0.78
$
3.18
$
2.84
$
2.42
$
2.07
$
1.65 (Loss)/income from discontinued operations
(0.01
)
(0.05
)
(0.20
)
(0.13
)
0.03
0.04
0.02 Net income
$
0.55
$
0.73
$
2.98
$
2.71
$
2.45
$
2.11
$
1.67 S-18
March 31,
Three Months Ended
Year Ended December 31,
2007(a)
2006
2006 (b)
2005 (g)
2004
2003 (h)
2002 (i)
(in thousands, except for per share data) Earnings per common share—diluted: (n) (o) Income from continuing operations
$
0.55
$
0.77
$
3.14
$
2.79
$
2.32
$
1.99
$
1.57 (Loss)/income from discontinued
(0.01
)
(0.05
)
(0.20
)
(0.13
)
0.03
0.03
0.02 Net income
$
0.54
$
0.72
$
2.94
$
2.66
$
2.35
$
2.02
$
1.59 Dividends per common share (n)
$
0.10
$
0.10
$
0.40
$
0.36
$
0.30
$
0.075
$
— Balance Sheet Data (at end of period): Cash and cash equivalents
$
158,397
$
156,461
$
149,640
$
92,130
$
73,302
$
154,958
$
96,777 Accounts receivable, net
810,576
775,724
774,414
732,907
649,281
609,187
522,131 Goodwill, net
3,724,768
3,199,238
3,391,046
3,197,227
2,506,950
2,518,875
1,788,850 Total assets
6,186,542
5,434,568
5,661,482
5,306,115
4,203,788
4,301,418
3,324,197 Long-term debt
1,238,265
1,240,501
1,239,105
1,255,386
724,021
1,028,707
796,507 Total debt
2,005,306
1,532,390
1,555,979
1,592,225
1,098,822
1,102,657
822,539 Total stockholders’ equity
3,029,232
2,865,296
3,019,171
2,762,984
2,288,651
2,394,694
1,768,863 Other Data: Net cash provided by operating activities
$
151,553
$
240,659
$
951,896
$
851,583
$
798,780
$
662,799
$
596,371 Net cash used in investing activities
(345,947
)
(27,991
)
(414,402
)
(1,079,793
)
(173,700
)
(417,050
)
(477,212
) Net cash (used in) provided by financing activities
(203,151
)
(148,337
)
(479,984
)
247,038
(706,736
)
(187,568
)
(144,714
) Provision for doubtful accounts
67,508
63,423
243,443
233,628
226,310
228,222
217,360 Rent expense
40,183
38,722
153,185
139,660
132,883
120,748
96,547 Capital expenditures
40,126
42,186
193,422
224,270
176,125
174,641
155,196 Depreciation and amortization
50,335
49,060
197,398
176,124
168,726
153,903
131,391
(a)
On January 31, 2007, we completed the acquisition of HemoCue, which generated annualized revenues of approximately $90 million. Consolidated operating results for 2007 include the results of
operations of HemoCue subsequent to the closing of the acquisition. (b) On July 3, 2006, we completed the acquisition of Focus Diagnostics, which generated annualized revenues of approximately $65 million. Consolidated operating results for 2006 include the results
of operations of Focus Diagnostics subsequent to the closing of the acquisition. See Note 3 to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year
ended December 31, 2006, which is incorporated by reference into this prospectus supplement. (c) During 2006, we recorded $55 million of stock-based compensation expense in accordance with SFAS 123R. (d) During 2006, we recorded $10 million related to net investment losses. The net investment losses of $10 million include a $15.8 million gain on the sale of an investment recorded during the first
quarter of 2006. (e) During 2006, we recorded $23 million in charges as a result of finalizing our plan of integration of LabOne, and $4.1 million in charges related to consolidating operations in California into a
new facility. S-19
March 31,
operations
(f) During 2006, we recorded $32 million in charges as a result of discontinuing NID’s operations. During the fourth quarter of 2005, we recorded a $16 million charge to write-off certain assets in
connection with a product hold at NID. (g) On November 1, 2005, we completed the acquisition of LabOne, which had annual revenues of approximately $468 million. Consolidated operating results for 2005 include the results of
operations of LabOne subsequent to the closing of the acquisition. See Note 3 to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended
December 31, 2006, which is incorporated by reference into this prospectus supplement. (h) On February 28, 2003, we completed the acquisition of Unilab Corporation, or Unilab. Consolidated operating results for 2003 include the results of operations of Unilab subsequent to the
closing of the acquisition. (i) On April 1, 2002, we completed the acquisition of American Medical Laboratories, Incorporated, or AML. Consolidated operating results for 2002 include the results of operations of AML
subsequent to the closing of the acquisition. (j) During 2005, we recorded a $6.2 million charge primarily related to forgiveness of amounts owed by patients and physicians, and related property damage as a result of hurricanes in the Gulf
Coast. (k) During 2004, we recorded a $10.3 million charge associated with the acceleration of certain pension obligations in connection with the succession of our prior Chief Executive Officer. (l) During 2005, we recorded a $7.1 million charge associated with the write-down of an investment. (m) During 2004, we recorded a $2.9 million charge to interest expense, net representing the write-off of deferred financing costs associated with the refinancing of our bank debt and credit facility. (n) Previously reported basic and diluted earnings per share have been restated to give retroactive effect of our two-for-one stock split effected on June 20, 2005. (o) Potentially dilutive common shares primarily include the dilutive effect of our 13/4% contingent convertible debentures issued November 26, 2001, which were redeemed principally through a
conversion into common shares as of January 18, 2005, and outstanding stock options, performance share units and restricted common shares granted under our Amended and Restated Employee
Long-Term Incentive Plan and our Amended and Restated Director Long-Term Incentive Plan. S-20
SELECTED HISTORICAL FINANCIAL DATA FOR AMERIPATH, INC. The following table summarizes selected historical financial data for AmeriPath, Inc. at the dates and for each of the periods presented. AmeriPath, Inc. derived the selected historical financial
data for the years 2002 through 2006 from its audited financial statements. AmeriPath, Inc. derived the selected historical financial data for the three months ended March 31, 2007 and 2006 from its
unaudited interim consolidated financial statements. On December 8, 2002, Amy Holding Company and its wholly-owned subsidiary, Amy Acquisition Corp., entered into a merger agreement with the
predecessor of AmeriPath, Inc., pursuant to which Amy Acquisition Corp. merged with and into the predecessor, with AmeriPath, Inc. continuing as the surviving corporation (the “March 2003
Transaction”). As a result of the March 2003 Transaction, AmeriPath, Inc. became a wholly-owned subsidiary of Amy Holding Company, which was renamed AmeriPath Holdings, Inc., or Holdings.
Amy Holding Company and Amy Acquisition Corp. were Delaware corporations formed at the direction of Welsh, Carson, Anderson & Stowe IX, L.P., or WCAS. The March 2003 Transaction was
approved by AmeriPath, Inc.’s stockholders and subsequently consummated on March 27, 2003. References herein to the “predecessor” refer to the activities, financial position and results of
operations of AmeriPath, Inc. prior to the March 2003 Transaction. AmeriPath, Inc.’s consolidated financial statements for the years ended December 31, 2006, 2005, and 2004, for the period from
March 28, 2003 through December 31, 2003, for the period from January 1, 2003 through March 27, 2003, and for the year ended December 31, 2002 have been audited by Ernst & Young LLP,
AmeriPath, Inc.’s independent auditors. STATEMENTS OF OPERATIONS(a)
Successor (b)
Predecessor (b)
Three Months Ended
Year Ended
Year Ended
Year Ended
Period from
Period from
Year Ended
2007
2006
2006(j)
2005
2004
2003
2003
2002
(dollars in thousands) Net revenues
$
200,694
$
170,936
$
752,321
$
563,617
$
507,271
$
366,046
$
118,957
$
478,818 Operating costs and expenses: Cost of services
117,005
96,926
418,082
298,932
270,959
189,771
62,145
238,573 Selling, general and administrative expenses
46,635
35,751
154,235
110,520
95,688
65,579
21,726
84,868 Provision for doubtful accounts
19,358
19,840
84,936
73,766
76,463
56,376
14,997
58,170 Amortization expense (c) (k)
2,515
3,264
13,127
13,585
13,761
10,379
3,107
11,641 Merger-related charges (d)
109
586
2,064
—
—
2,404
10,010
2,836 Restructuring costs (e)
—
—
—
—
—
2,044
1,196
— Asset impairment and related charges (f)
—
—
—
883
611
425
—
2,753 Total operating costs and expenses
185,622
156,367
672,444
497,686
457,482
326,978
113,181
398,841 Income from operations
15,072
14,569
79,877
65,931
49,789
39,068
5,776
79,977 Interest expense (k)
(15,043
)
(13,693
)
(57,432
)
(46,527
)
(42,136
)
(32,442
)
(1,180
)
(3,764
) Change in value of derivative (g)
—
293
1,295
(280
)
(1,015
)
—
—
— Write-off of Genomics investment (h)
—
—
—
—
—
—
—
(1,000
) Write-off of deferred financing costs (i)
—
(3,360
)
(3,388
)
(468
)
(3,829
)
—
(957
)
— Other income, net
393
338
1,516
620
66
318
33
548 Income (loss) before income taxes
422
(1,853
)
21,868
19,276
2,875
6,944
3,672
75,761 Provision for income taxes
203
237
11,341
9,355
1,361
3,090
2,131
31,120 Net income (loss)
$
219
$
(2,090
)
$
10,527
$
9,921
$
1,514
$
3,854
$
1,541
$
44,641 S-21
March 31,
December 31,
December 31,
December 31,
March 28
through
December 31,
January 1
through
March 27,
December 31,
CONSOLIDATED BALANCE SHEET DATA(a)
March 31,
December 31,
2007
2006
2006
2005
2004
2003
2002
(dollars in thousands) Cash and cash equivalents
$
—
$
8,648
$
182
$
3,998
$
20,980
$
23,536
$
964 Restricted cash
29,601
26,829
30,906
26,684
17,940
12,825
8,453 Total assets
1,437,234
1,340,786
1,411,101
984,149
964,309
912,753
708,460 Long-term debt, including current portion
625,534
610,826
624,259
479,490
497,853
492,458
116,253 Stockholders’ equity
629,932
565,563
606,340
384,717
358,092
338,675
451,326
(a)
This presentation is for AmeriPath, Inc. We acquired AmeriPath Group Holdings, Inc., the ultimate parent of AmeriPath, Inc., whose principal assets consisted of cash (which was used to repay
debt) and its indirect investment in AmeriPath, Inc., and whose principal liabilities consisted of debt, which was repaid in connection with the acquisition of AmeriPath Group Holdings, Inc. As
of the date hereof, AmeriPath Group Holdings, Inc. has no significant assets other than its indirect investment in AmeriPath, Inc. (b) Consolidated financial data for periods subsequent to March 27, 2003 reflect the fair value of assets acquired and liabilities assumed in connection with the March 2003 Transaction. The
comparability of the operating results for the periods presented is affected by the revaluation of the assets acquired and liabilities assumed on the date of the March 2003 Transaction. The
financial data for the periods prior to March 28, 2003 consist of the historical data of AmeriPath, Inc. and subsidiaries prior to the March 2003 Transaction. (c) The predecessor adopted the provisions of SFAS No. 142 as of January 1, 2002. SFAS 142 clarifies the criteria to recognize intangible assets separately from goodwill and promulgates that
goodwill and certain indefinite-lived intangible assets not be amortized. (d) In connection with the March 2003 Transaction, AmeriPath, Inc. recorded $2.8 million of transaction fees in the fourth quarter of 2002 and $12.4 million during 2003. In 2006, AmeriPath, Inc.
recorded $2.1 million of transaction fees related to the Specialty acquisition. (e) Represents restructuring costs that were recognized based upon criteria set forth in SFAS 146 of (i) $1.2 million for employee severance costs in connection with a reduction in workforce at
AmeriPath, Inc.’s Southern California, Philadelphia, Central Florida and North Texas laboratories, and (ii) $2.0 million incurred for remaining severance costs and the closure of AmeriPath, Inc.’s
Southern California laboratory. The Southern California facility was closed as a result of a loss of revenue from Quest Diagnostics, which historically accounted for a significant portion of
revenues for this individual lab. (f) During 2002, AmeriPath, Inc. recorded charges consisting of approximately $2.1 million in connection with the write-off of its remaining Quest Diagnostics laboratory contract intangibles and
approximately $0.7 million in connection with its termination of a management service agreement in Georgia. During 2003, AmeriPath, Inc. recorded a pre-tax, non-cash charge of approximately
$0.4 million in connection with the sale of two hospital-based practices in Florida. During 2004, AmeriPath, Inc. recorded a pre-tax, non-cash charge of approximately $0.6 million in connection
with the sale of a practice in Michigan. In August 2005, AmeriPath, Inc. sold its managed practice in Memphis, Tennessee. As a result of the sale, AmeriPath, Inc. recognized a loss of
approximately $1.3 million. As a result of the sale and termination of the Memphis managed service agreement, AmeriPath, Inc. performed an impairment analysis relative to the carrying value of
this identifiable intangible and determined that no impairment existed at September 30, 2005. In February 2005, AmeriPath, Inc. sold a managed practice in Los Gatos, California resulting in a
gain of approximately $0.4 million. S-22
(g) During 2004, AmeriPath, Inc. entered into a swap agreement, and recorded its change in market value as of December 31, 2004, 2005, and 2006, respectively. On October 2, 2006, AmeriPath, Inc.
terminated the agreement. (h) During 2002, AmeriPath, Inc. wrote off the $1.0 million carrying value of its interest in a genomics company as a result of a decline in the fair value of this investment. (i) Consists of write-offs of deferred financing costs relating to the March 2003 Transaction, and two voluntary paydowns on AmeriPath, Inc.’s current credit facility in both 2004 and 2005. In January
2006, in connection with the acquisition of Specialty, AmeriPath, Inc. terminated its existing credit facility and entered into a new senior credit facility. As a result of terminating the credit
facility, AmeriPath, Inc. wrote-off approximately $3.4 million of its deferred debt financing costs. (j) The statement of income for 2006 includes the results of Specialty from the effective date of the acquisition by AmeriPath, Inc., which was January 31, 2006. Net revenues from Specialty for the
year ended December 31, 2006 were $148.1 million. (k) For the three months ended March 31, 2007 and 2006, amortization of deferred debt costs of $0.7 million and $0.6 million, respectively, are included in interest expense versus amortization
expense as it is presented in the annual information. S-23
Each of the 6.40% senior notes due 2017 (the “Notes due 2017”) and the 6.95% senior notes due 2037 (the “Notes due 2037” and, together with the Notes due 2017, the “Notes”) are a separate
issue of debt securities. The notes will be issued under an indenture dated as of June 27, 2001 as supplemented by a supplemental indenture, dated as of June 27, 2001, each among Quest Diagnostics,
as issuer, the Initial Subsidiary Guarantors, as guarantors, and The Bank of New York, as trustee, as further supplemented by a second supplemental indenture, dated as of November 26, 2001, among
Quest Diagnostics, the Subsidiary Guarantors and The Bank of New York, as further supplemented by a third supplemental indenture, dated as of April 4, 2002, among Quest Diagnostics, the
additional Subsidiary Guarantors and The Bank of New York, as further supplemented by a fourth supplemental indenture, dated as of March 19, 2003, among Quest Diagnostics, the additional
Subsidiary Guarantors and The Bank of New York, as further supplemented by a supplemental indenture, dated as of April 16, 2004, among Quest Diagnostics, the additional Subsidiary Guarantor
and The Bank of New York, as further supplemented by a sixth supplemental indenture dated October 31, 2005, as further supplemented by a seventh supplemental indenture dated November 21,
2005, among Quest Diagnostics, the additional Subsidiary Guarantors and The Bank of New York, as further supplemented by an eighth supplemental indenture dated July 31, 2006, among Quest
Diagnostics, the additional Subsidiary Guarantors and The Bank of New York and as further supplemented by the ninth supplemental indenture dated September 30, 2006, among Quest Diagnostics,
the additional Subsidiary Guarantors and The Bank of New York and as to be amended by a tenth supplemental indenture to be dated as of the closing date of this offering (collectively, the
“Indenture”). On June 7, 2001, we completed a $550 million senior notes offering under the Indenture and on October 31, 2005, we completed a $900 million senior notes offering under the
Indenture. The terms of the Notes include those stated in the Indenture and those made part of the Indenture by reference to the Trust Indenture Act of 1939. A copy of the Indenture is available
for inspection at the office of the trustee. Whenever we refer in this “Description of Notes” to terms defined in the Indenture below, such defined terms are incorporated herein by reference. As used in this “Description of Notes,” the
terms “we,” “our,” “us” and “Quest Diagnostics” do not include any current or future subsidiary of Quest Diagnostics Incorporated, unless the context indicates otherwise. General The Notes due 2017 will be initially limited to $375,000,000 aggregate principal amount and will mature and become due and payable, together with any accrued and unpaid interest thereon, on
July 1, 2017. The Notes due 2037 will be initially limited to $425,000,000 aggregate principal amount and will mature and become due and payable, together with any accrued and unpaid interest
thereon, on July 1, 2037. Quest Diagnostics may from time to time, without the consent of the holders of the Notes, issue additional Notes of either series having the same ranking and the same interest rate, maturity
and other terms as the Notes of the applicable series. Any additional Notes and the Notes of such series will generally constitute a single series under the Indenture. This type of offering is often
referred to as a “re-opening.” Additional Notes may constitute a separate issuance for United States federal income tax purposes. Notes of either series will bear interest at the annual rate noted on the cover page of this prospectus supplement. Interest will be payable semiannually on July 1 and January 1 of each year,
beginning January 1, 2008. Interest on the Notes will be paid to holders of record on the June 15 or December 15 immediately before the applicable interest payment date. The Notes do not provide for any sinking fund. Guarantees Each Subsidiary Guarantor will fully and unconditionally guarantee, on a joint and several basis, the payment of the principal of, and any premium and interest on the Notes. The guarantees of
the S-24
Notes will be endorsed on the Notes. In addition, each future domestic Subsidiary of Quest Diagnostics, or any Subsidiary Guarantor which has been released and discharged from its obligations
under the guarantee of the Notes, will be required to guarantee Quest Diagnostics’ obligations under the Notes, if such Subsidiary:
•
guarantees any Indebtedness of Quest Diagnostics when the amount of such Indebtedness, together with any other outstanding Indebtedness of Quest Diagnostics guaranteed by its Subsidiaries
that are not Subsidiary Guarantors, exceeds $50 million in the aggregate at any time; or • incurs Indebtedness, unless such Indebtedness is permitted under the “—Limitation on Subsidiary Indebtedness and Preferred Stock” covenant described below; provided, however, for the avoidance of doubt, the Specified Subsidiaries are not subject to the foregoing until such time, if any, the Specified Subsidiaries become Subsidiary Guarantors. The Specified Subsidiaries are not guaranteeing the Notes, but will guarantee the term loans, the senior unsecured revolving credit facility and the existing senior notes of Quest Diagnostics. The Indenture provides that the obligations of each Subsidiary Guarantor under its guarantee will be limited so as to not constitute a fraudulent conveyance under any United States federal or
state laws. Application of this clause could limit the amount which holders of Notes may be entitled to collect under the guarantees. Holders, by their acceptance of the Notes, will have agreed to
such limitations. See “Risk Factors—Federal and state laws permit a court to void a guarantee issued by any of our subsidiaries if the court finds the guarantee to constitute a fraudulent conveyance.” The guarantees of the Subsidiary Guarantors with respect to the Notes will remain in effect with respect to each Subsidiary Guarantor until the entire amount of principal of, premium, and
interest on the Notes shall have been paid in full or otherwise discharged in accordance with the provisions of the Indenture; provided, however, that if (a) a Subsidiary Guarantor does not guarantee
Indebtedness of Quest Diagnostics the amount of which, when added together with any other outstanding Indebtedness of Quest Diagnostics guaranteed by its Subsidiaries that are not Subsidiary
Guarantors, would exceed $50 million in the aggregate, excluding the Notes, and all outstanding Indebtedness of such Subsidiary Guarantor would have been permitted to be incurred under the
“—Limitation on Subsidiary Indebtedness and Preferred Stock” covenant described below measured at the time of the release and discharge as described in this paragraph, (b) the Notes are defeased
and discharged as described under “Defeasance” or (c) all or substantially all of the assets of such Subsidiary Guarantor or all of the capital stock of such Subsidiary Guarantor is sold (including by
issuance, merger, consolidation or otherwise) by Quest Diagnostics or any of its Subsidiaries, then in each case of (a), (b) or (c) above, such Subsidiary Guarantor or the corporation acquiring such
assets (in the event of a sale or other disposition of all or substantially all of the assets or capital stock of such Subsidiary Guarantor) shall be released and discharged from its obligations under its
guarantee of the Notes. Seniority; Ranking The Notes will be senior unsecured obligations of Quest Diagnostics and will rank equally with other existing and future senior unsecured obligations of Quest Diagnostics. Each guarantee will be
a senior unsecured obligation of the Subsidiary Guarantor issuing such guarantee and will rank equally with other existing and future senior unsecured obligations of such Subsidiary Guarantor. As of
March 31, 2007, after giving effect to the Transactions, Quest Diagnostics and the Subsidiary Guarantors would have had total debt outstanding of $3.64 billion. The Notes and the guarantees will be effectively subordinated to any secured obligations of Quest Diagnostics or Subsidiary Guarantors, as the case may be, to the extent of the value of the
assets securing such obligations. The Indenture does not limit the amount of indebtedness that Quest Diagnostics and any of its subsidiary guarantors can incur, but does limit the amount of
indebtedness its non-guarantor subsidiaries are permitted to incur (as described below). In addition, the Indenture limits the amount of secured indebtedness pursuant to the covenant described under
the heading “Description of Notes—Limitation on Liens.” This covenant is subject to important exceptions S-25
described under such heading. As of March 31, 2007, after giving effect to the Transactions, Quest Diagnostics and the Subsidiary Guarantors would have had secured debt outstanding of $5.5 million. Quest Diagnostics conducts its operations through subsidiaries, which generate a substantial portion of its operating income and cash. As a result, distributions or advances from subsidiaries of
Quest Diagnostics are a major source of funds necessary to meet its debt service and other obligations. Contractual provisions, laws or regulations, as well as any subsidiary’s financial condition and
operating requirements, may limit the ability of Quest Diagnostics to obtain cash required to pay Quest Diagnostics’ debt service obligations, including payments on the Notes. The Notes will be structurally subordinated to all existing and future obligations of Quest Diagnostics’ subsidiaries (unless such subsidiaries are Subsidiary Guarantors), including claims with
respect to trade payables. In addition, the guarantees of our Subsidiary Guarantors will be structurally subordinated to all existing and future obligations of any subsidiary of ours or a Subsidiary
Guarantor (unless such subsidiaries are also Subsidiary Guarantors), including claims with respect to trade payables. This means that holders of the Notes as guaranteed by the Subsidiary Guarantors
will have a junior position to the claims of creditors of the direct and indirect subsidiaries of Quest Diagnostics which are not Subsidiary Guarantors on the assets and earnings of such subsidiaries.
The non-guarantor subsidiaries of Quest Diagnostics are limited in the amount of Indebtedness they are permitted to incur pursuant to the covenant described under “—Limitation of Subsidiary
Indebtedness and Preferred Stock.” This covenant is subject to important exceptions described under such heading. In addition, the guarantees of the Subsidiary Guarantors may be released in certain
circumstances, which are described under the heading “—Guarantees.” As of March 31, 2007, after giving effect to the Transactions, the non-guarantor subsidiaries of Quest Diagnostics would have had
outstanding $314 million of debt (including the current portion thereof) of which $300 million was comprised of the Existing Receivables Credit Facility. In addition, after giving effect to the
Transactions, the Specified Subsidiaries will not be required to guarantee the notes offered hereby but will guarantee the term loans and the senior notes of Quest Diagnostics ($2.83 billion
collectively as of March 31, 2007) after giving effect to the Transactions. For a more detailed description of our Existing Receivables Credit Facility, see “Description of Certain Other
Indebtedness—Secured Receivables Credit Facility.” Optional Redemption At any time and from time to time, the Notes of each series will be redeemable, as a whole or in part, at the option of Quest Diagnostics, on at least 30 days, but not more than 60 days, prior
notice mailed to the registered address of each holder of the Notes of the applicable series, at a redemption price equal to the greater of:
•
100% of principal amount of the Notes to be redeemed, and • the sum of the present values of the Remaining Scheduled Payments (as defined below) discounted, on a semiannual basis, assuming a 360-day year consisting of twelve 30-day months, at the
Treasury Rate (as defined below) plus: 25 basis points for the 6.40% Notes due 2017, or 30 basis points for the 6.95% Notes due 2037, plus accrued interest to the date of redemption which has not been paid. On and after the redemption date for the Notes of either series, interest will cease to accrue on the Notes of that series or any portion thereof called for redemption, unless Quest Diagnostics
defaults in the payment of the redemption price and accrued interest. On or before the redemption date for the Notes of that series, Quest Diagnostics shall deposit with a paying agent, or the
trustee, funds sufficient to pay the redemption price of and accrued interest on such Notes to be redeemed on such date. If less than all of the Notes of a series are to be redeemed, the Notes of that
series to be redeemed shall be selected by the trustee by such method as the trustee shall deem fair and appropriate. S-26
“Remaining Scheduled Payments” means, with respect to the Notes of either of the series to be redeemed, the remaining scheduled payments of the principal thereof and interest thereon that
would be due after the related redemption date but for such redemption; provided, however, that, if such redemption date is not an interest payment date with respect to the Notes, the amount of the
next succeeding scheduled interest payment thereon will be deemed to be reduced by the amount of interest accrued thereon to such redemption date. “Treasury Rate” means, with respect to any redemption date for the Notes of either series:
•
the yield, which represents the average for the immediately preceding week, appearing in the most recently published statistical release designated “H.15(519)” or any successor publication
which is published weekly by the Board of Governors of the Federal Reserve System and which establishes yields on actively traded United States Treasury securities adjusted to constant
maturity under the caption “Treasury Constant Maturities,” for the maturity corresponding to the Comparable Treasury Issue; provided that if no maturity is within three months before or after
the maturity date for the Notes, yields for the two published maturities most closely corresponding to the Comparable Treasury Issue will be determined and the Treasury Rate will be
interpolated or extrapolated from those yields on a straight line basis, rounding to the nearest month; or • if that release, or any successor release, is not published during the week preceding the calculation date or does not contain such yields, the rate per annum equal to the semiannual equivalent
yield to maturity of the Comparable Treasury Issue, calculated using a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable
Treasury Price for that redemption date. The Treasury Rate will be calculated on the third business day preceding the redemption date. “Comparable Treasury Issue” means the United States Treasury security selected by an Independent Investment Banker as having a maturity comparable to the remaining term of the Notes due
2017 or the Notes due 2037, as the case may be, to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate
debt securities of comparable maturity to the remaining term of the Notes. “Independent Investment Banker” means one of the Reference Treasury Dealers, to be appointed by Quest Diagnostics. “Comparable Treasury Price” means, with respect to any redemption date for the Notes:
•
the average of four Reference Treasury Dealer Quotations for that redemption date, after excluding the highest and lowest of such Reference Treasury Dealer Quotations; or • if the trustee obtains fewer than four Reference Treasury Dealer Quotations, the average of all quotations obtained by the trustee. “Reference Treasury Dealer Quotations” means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined by the trustee, of the bid and asked prices
for the Comparable Treasury Issue, expressed in each case as a percentage of its principal amount, quoted in writing to the trustee by such Reference Treasury Dealer at 3:30 p.m., New York City
time, on the third business day preceding such redemption date. “Reference Treasury Dealer” means a primary U.S. Government securities dealer, which we refer to as “Primary Treasury Dealer,” selected by Quest Diagnostics. Change of Control If a Change of Control Triggering Event occurs, unless Quest Diagnostics has exercised its option to redeem the Notes as described above, Quest Diagnostics will be required to make an offer
(the “Change of Control Offer”) to each holder of the Notes to repurchase all or any part (equal to $2,000 or an integral multiple of $1,000 in excess thereof) of that holder’s Notes on the terms set
forth in the Notes. In the Change of Control Offer, Quest Diagnostics will be required to offer payment in cash equal to 101% of the aggregate principal amount of Notes repurchased, plus accrued
and unpaid interest, if any, on the Notes repurchased to the date of repurchase (the S-27
“Change of Control Payment”). Within 30 days following any Change of Control Triggering Event or, at Quest Diagnostics’ option, prior to any Change of Control, but after public announcement of
the transaction that constitutes or may constitute the Change of Control, a notice will be mailed to holders of the Notes describing the transaction that constitutes or may constitute the Change of
Control Triggering Event and offering to repurchase the Notes on the date specified in the notice, which date will be no earlier than 30 days and no later than 60 days from the date such notice is
mailed (the “Change of Control Payment Date”). The notice will, if mailed prior to the date of consummation of the Change of Control, state that the offer to purchase is conditioned on the Change
of Control Triggering Event occurring on or prior to the Change of Control Payment Date. On the Change of Control Payment Date, Quest Diagnostics will, to the extent lawful:
•
accept for payment all Notes or portions of Notes properly tendered pursuant to the Change of Control Offer; • deposit with the paying agent an amount equal to the Change of Control Payment in respect of all Notes or portions of Notes properly tendered; and • deliver or cause to be delivered to the trustee the Notes properly accepted together with an officers’ certificate stating the aggregate principal amount of Notes or portions of Notes being
repurchased. Quest Diagnostics will not be required to make a Change of Control Offer upon the occurrence of a Change of Control Triggering Event if a third party makes such an offer in the manner, at
the times and otherwise in compliance with the requirements for an offer made by Quest Diagnostics and the third party repurchases all Notes properly tendered and not withdrawn under its offer. In
addition, Quest Diagnostics will not repurchase any Notes if there has occurred and is continuing on the Change of Control Payment Date an event of default under the indenture, other than a
default in the payment of the Change of Control Payment upon a Change of Control Triggering Event. Quest Diagnostics will comply with the requirements of Rule 14e-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any other securities laws and regulations
thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the Notes as a result of a Change of Control Triggering Event. To the extent that the
provisions of any such securities laws or regulations conflict with the Change of Control Offer provisions of the Notes, Quest Diagnostics will comply with those securities laws and regulations and
will not be deemed to have breached its obligations under the Change of Control Offer provisions of the Notes by virtue of any such conflict. For purposes of the Change of Control Offer provisions
of the Notes, the following terms will be applicable: “Change of Control” means the occurrence of any of the following: (1) the consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that
any “person” (as that term is used in Section 13(d) (3) of the Exchange Act) (other than Quest Diagnostics or one of its subsidiaries) becomes the beneficial owner (as defined in Rules 13d-3 and
13d-5 under the Exchange Act), directly or indirectly, of more than 50% of the voting stock of Quest Diagnostics or other voting stock into which the voting stock of Quest Diagnostics is reclassified,
consolidated, exchanged or changed, measured by voting power rather than number of shares; (2) the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or
consolidation), in one or more series of related transactions, of all or substantially all of Quest Diagnostics’ assets and the assets of its subsidiaries, taken as a whole, to one or more “persons” (as
that term is defined in the indenture) (other than Quest Diagnostics or one of its subsidiaries); or (3) the first day on which a majority of the members of the Board of Directors of Quest Diagnostics
are not Continuing Directors. Notwithstanding the foregoing, a transaction will not be deemed to involve a Change of Control if (1) Quest Diagnostics becomes a direct or indirect wholly-owned
subsidiary of a holding company and (2)(A) the direct or indirect holders of the voting stock of such holding company immediately following that transaction are substantially the same as the holders
of the voting stock of Quest Diagnostics immediately prior to that transaction or (B) immediately following that transaction no person (other than a holding company satisfying the requirements of
this sentence) is the beneficial owner, directly or indirectly, of more than 50% of the voting stock of such holding company. S-28
“Change of Control Triggering Event” means the occurrence of both a Change of Control and a Rating event. “Continuing Directors” means, as of any date of determination, any member of Quest Diagnostics’ Board of Directors who (1) was a member of such Board of Directors on the date the Notes
were issued or (2) was nominated for election, elected or appointed to such Board of Directors with the approval of a majority of the Continuing Directors who were members of such Board of
Directors at the time of such nomination, election or appointment (either by a specific vote or by approval of the proxy statement of Quest Diagnostics in which such member was named as a
nominee for election as a director, without objection to such nomination). “Fitch” means Fitch Ratings. “Investment Grade Rating” means a rating equal to or higher than Baa3 (or the equivalent) by Moody’s and BBB– (or the equivalent) by S&P, and the equivalent investment grade credit rating
from any additional rating agency or Rating Agencies selected by Quest Diagnostics. “Moody’s” means Moody’s Investors Service, Inc. “Rating Agencies” means (1) each of Moody’s and S&P and Fitch, to the extent Fitch makes a rating of the Notes publicly available; and (2) if any of Moody’s and S&P or Fitch, to the extent Fitch
makes a rating of the Notes publicly available, ceases to rate the Notes or fails to make a rating of the Notes publicly available for reasons outside of the control of Quest Diagnostics, a “nationally
recognized statistical rating organization” within the meaning of Rule 15c3-1(c)(2)(vi)(F) under the Exchange Act selected by Quest Diagnostics (as certified by a resolution of the Board of Directors)
as a replacement agency for Moody’s or S&P or Fitch (if applicable), or all of them, as the case may be. “Rating event” means the rating on the Notes is lowered by each of the Rating Agencies and the Notes are rated below an Investment Grade Rating by each of the Rating Agencies on any day
within the 60-day period (which 60-day period will be extended so long as the rating of the Notes is under publicly announced consideration for a possible downgrade by any of the Rating Agencies)
after the earlier of (1) the occurrence of a Change of Control and (2) public notice of the occurrence of a Change of Control or the intention of Quest Diagnostics to effect a Change of Control;
provided, however, that a rating event otherwise arising by virtue of a particular reduction in rating will not be deemed to have occurred in respect of a particular Change of Control (and thus will
not be deemed a rating event for purposes of the definition of Change of Control Triggering Event) if the Rating Agencies making the reduction in rating to which this definition would otherwise
apply do not announce or publicly confirm or inform the trustee in writing at its request or the request of Quest Diagnostics that the reduction was the result, in whole or in part, of any event or
circumstance comprised of or arising as a result of, or in respect of, the applicable Change of Control (whether or not the applicable Change of Control has occurred at the time of the rating event). “S&P” means Standard & Poor’s Rating Services, a division of The McGraw-Hill Companies, Inc. “Voting stock” means, with respect to any specified “person” (as that term is used in Section 13(d)(3) of the Exchange Act) as of any date, the capital stock of such person that is at the time
entitled to vote generally in the election of the board of directors of such person. Sinking Fund The Notes will not be entitled to the benefit of any sinking fund. Limitation on Liens Other than as provided under “—Exempted Liens and Sale and Leaseback Transactions,” Quest Diagnostics will not, and will not permit any Restricted Subsidiary to, create or assume any
Indebtedness secured by any Lien on any Principal Property or shares of stock or Indebtedness of any Restricted Subsidiary, unless: (1) in the case of Quest Diagnostics, the Notes are secured by S-29
such Lien equally and ratably with, or prior to, the Indebtedness secured by such Lien, or (2) in the case of any Subsidiary Guarantor, such Subsidiary Guarantor’s guarantee of the Notes is secured
by such Lien equally and ratably with, or prior to, the Indebtedness secured by such Lien. The restrictions do not apply to Indebtedness that is secured by:
•
Liens existing on the date of the issuance of the Notes; • Liens securing only the Notes; • Liens in favor of only Quest Diagnostics or any Restricted Subsidiary; • Liens on property or shares of stock or indebtedness of a Person existing at the time such Person becomes a Restricted Subsidiary or is merged into or consolidated with, or its assets are
acquired by, Quest Diagnostics or any Restricted Subsidiary (provided that such Lien was not incurred in anticipation of such transaction and was in existence prior to such transaction) so long
as such Lien does not extend to any other property and the Indebtedness so secured is not increased; • Liens on property existing immediately prior to the acquisition thereof (provided that such Lien was not incurred in anticipation of such transaction and was in existence prior to such
transaction) so long as such Lien does not extend to any other property and the Indebtedness so secured is not increased; • Liens to secure Indebtedness incurred for the purpose of all or any part of a property’s purchase price or cost of construction or additions, repairs, alterations, or other improvements; provided
that (1) the principal amount of any Indebtedness secured by such Lien does not exceed 100% of such property’s purchase price or cost, (2) such Lien does not extend to or cover any other
property other than the property so purchased, constructed or on which such additions, repairs, alterations or other improvements were so made, and (3) such Lien is incurred prior to or within
270 days after the acquisition of such property or the completion of construction or such additions, repairs, alterations or other improvements and the full operation of such property thereafter; • Liens in favor of the United States or any state thereof, or any instrumentality of either, to secure certain payments pursuant to any contract or statute; • Liens for taxes or assessments or other governmental charges or levies which are being contested in good faith and for which adequate reserves are being maintained, to the extent required by
generally accepted accounting principles; • title exceptions, easements and other similar Liens that are not consensual and that do not materially impair the use of the property subject thereto; • Liens to secure obligations under workmen’s compensation laws, unemployment compensation, old-age pensions and other social security benefits or similar legislation, including Liens with
respect to judgments which are not currently dischargeable; • Liens arising out of legal proceedings, including Liens arising out of judgments or awards; • warehousemen’s, materialmen’s and other similar Liens for sums being contested in good faith and for which adequate reserves are being maintained, to the extent required by generally
accepted accounting principles; • Liens incurred to secure the performance of statutory obligations, surety or appeal bonds, performance or return-of-money bonds or other obligations of a like nature incurred in the ordinary
course of business; or • Liens to secure any extension, renewal, refinancing or refunding (or successive extensions, renewals, refinancings or refundings), in whole or in part, of any Indebtedness secured by Liens
referred to in the foregoing bullets or liens created in connection with any amendment, consent or waiver relating to such Indebtedness, so long as such Lien does not extend to any other
property and the Indebtedness so secured does not exceed the fair market value (as determined by our board of directors) of the assets subject to such Liens at the time of such extension,
renewal, refinancing or refunding, or such amendment, consent or waiver, as the case may be. S-30
Limitation on Sale and Leaseback Transactions Other than as provided under “—Exempted Liens and Sale and Leaseback Transactions,” Quest Diagnostics will not, and will not permit any Restricted Subsidiary to, enter into any Sale and
Leaseback Transaction with respect to any Principal Property unless:
•
the Sale and Leaseback Transaction is solely with Quest Diagnostics or a Subsidiary Guarantor; or • the lease is for a period not in excess of five years, including renewal rights; or • Quest Diagnostics or the Restricted Subsidiary, prior to or within 270 days after the sale of such Principal Property in connection with the Sale and Leaseback Transaction is completed, applies
the net cash proceeds of the sale of the Principal Property leased to:
(1)
the retirement of the Notes or debt ranking equally with the Notes of Quest Diagnostics or any Restricted Subsidiary, or (2) the acquisition of different property, facilities or equipment or the expansion of Quest Diagnostics’ existing business, including the acquisition of other businesses. Exempted Liens and Sale and Leaseback Transactions Notwithstanding the restrictions described under the headings “—Limitation on Liens” or “—Limitation on Sale and Leaseback Transactions,” Quest Diagnostics or any Restricted Subsidiary may
create or assume any Liens or enter into any Sale and Leaseback Transactions not otherwise permitted as described above, if the sum of the following does not exceed 5% of Consolidated Total
Assets:
•
the outstanding Indebtedness secured by such Liens (not including any Liens permitted under “—Limitation on Liens” which amount does not include any Liens permitted under the provisions of
this “—Exempted Liens and Sale and Leaseback Transactions”); plus • all Attributable Debt in respect of such Sale and Leaseback Transaction entered into (not including any Sale and Leaseback Transactions permitted under “—Limitation on Sale and Leaseback
Transactions” which amount does not include any Sale and Leaseback Transactions permitted under the provisions of this “—Exempted Liens and Sale and Leaseback Transactions”), measured, in each case, at the time such Lien is incurred or any such Sale and Leaseback Transaction is entered into by Quest Diagnostics or the Restricted Subsidiary. Limitation on Subsidiary Indebtedness and Preferred Stock None of the Subsidiaries of Quest Diagnostics other than the Subsidiary Guarantors may, directly or indirectly, create, incur, issue, assume or extend the maturity of any Indebtedness (including
Acquired Indebtedness) or Preferred Stock except for the following, provided that, for purposes of this covenant, any Acquired Indebtedness shall not be deemed to have been incurred until 270 days
from the date (1) the Person obligated on such Acquired Indebtedness becomes a Subsidiary of Quest Diagnostics or (2) the acquisition of assets, in connection with which such Acquired
Indebtedness was assumed, is consummated:
•
Indebtedness outstanding on the date of the Indenture; • Indebtedness representing the assumption by one Subsidiary of Indebtedness of another Subsidiary; • Indebtedness outstanding under any Receivables Credit Facility; • Indebtedness secured by a Lien incurred for the purpose of all or any part of a property’s purchase price or cost of construction or additions, repairs, alterations or other improvements,
provided that such Indebtedness and Lien is incurred prior to or within 270 days after the acquisition of such property or the completion of construction or such additions, repairs, alterations or
other improvements and the full operation of such property thereafter; S-31
• Indebtedness of any Subsidiary of Quest Diagnostics, the proceeds of which are used to renew, extend, refinance or refund outstanding Indebtedness of such Subsidiary; provided that such
Indebtedness is scheduled to mature no earlier than the Indebtedness being renewed, extended, refinanced or refunded; provided further that such Indebtedness shall be permitted hereunder
only to the extent that the aggregate principal amount of such Indebtedness (or, if such Indebtedness is issued at a price less than the principal amount thereof, the aggregate amount of gross
proceeds therefrom) does not exceed the aggregate principal amount then outstanding under the Indebtedness being renewed, extended, refinanced or refunded (or if the Indebtedness being
renewed, extended, refinanced or refunded, was issued at a price less than the principal amount thereof, then not in excess of the amount of liability in respect thereof determined in accordance
with generally accepted accounting principles) plus the lesser of (A) the stated amount of any premium or other payment required to be paid in connection with such a refinancing pursuant to
the terms of the Indebtedness being refinanced or (B) the amount of premium or other payment actually paid at such time to refinance the Indebtedness, plus, in either case, the amount of
expenses of such Subsidiary incurred in connection with such refinancing; • Indebtedness of a Subsidiary of Quest Diagnostics to Quest Diagnostics or to another Subsidiary of Quest Diagnostics; • any Indebtedness resulting from a Sale and Leaseback Transaction which is permitted by the “—Limitation on Sale and Leaseback Transactions” covenant (but not including any Sale and
Leaseback Transaction which is permitted by the “—Exempted Liens and Sale and Leaseback Transactions” provisions relating thereto); • any Permitted Acquired Indebtedness; • any guarantee of Indebtedness of Quest Diagnostics by the Specified Subsidiaries or any other Subsidiary of Quest Diagnostics in anticipation of such Subsidiary becoming a Subsidiary
Guarantor pursuant to the “—Guarantees” provision; • Preferred Stock to the extent that the aggregate liquidation preference of Preferred Stock, outstanding at any one time, does not exceed 5% of Consolidated Total Assets; or • any Indebtedness, including any Acquired Indebtedness that is not Permitted Acquired Indebtedness, the outstanding aggregate principal amount of which does not at any one time exceed the
greater of (1) 10% of Consolidated Total Assets or (2) $200 million, measured in each case at the time such Indebtedness is incurred. Limitation on restricted payments to certain non-guarantor subsidiaries Quest Diagnostics will not, and will not permit any Subsidiary to, (1) declare or pay any dividend or make any distribution to the Specified Subsidiaries on or in respect of its Capital Stock, (2)
purchase, redeem, retire or otherwise acquire for value from the Specified Subsidiaries any of its Capital Stock, or (3) purchase or otherwise acquire any assets, or purchase or otherwise acquire,
redeem, retire or repay any Indebtedness of the Specified Subsidiaries, or (4) make any investment in or make any loan to or transfer any assets to any of the Specified Subsidiaries. This covenant
will permanently cease to be in effect when each of the Specified Subsidiaries becomes a Subsidiary Guarantor. “Capital Stock” means, with respect to any Person, any and all shares or common stock or Preferred Stock. Merger, Consolidation or Sale of Assets Quest Diagnostics may merge or consolidate with another Person and may sell, transfer or lease all or substantially all of its assets to another Person if all the following conditions are met:
•
The merger, consolidation or sale of assets must not cause an event of default. See “—Events of Default.” An event of default for this purpose would also include any event that would be an
event of default if the notice or time requirements were disregarded;
S-32
• If Quest Diagnostics is not the surviving entity, the Person we would merge or consolidate with, or sell all or substantially all of our assets to, must be organized under the laws of the United
States or any state thereof; • If Quest Diagnostics is not the surviving entity, the Person we would merge or consolidate with, or sell all or substantially all of our assets to, must expressly assume by supplemental indenture
all of our obligations under the Notes and the Indenture; and • Quest Diagnostics must deliver specific certification and documents to the trustee. Events of Default The term “Event of Default” in respect of the Notes means any of the following:
Quest Diagnostics or any Subsidiary Guarantor does not pay the principal of or any premium on the Notes of that series on its due date; • Quest Diagnostics or any Subsidiary Guarantor does not pay interest on the Notes of that series within 30 days of its due date whether at maturity, upon redemption or upon acceleration; • Quest Diagnostics or any Subsidiary Guarantor remains in breach of a covenant in respect of the Notes of that series for 60 days after it receives a written notice of default stating it is in
breach and requiring that it remedy the breach. The notice must be sent by either the trustee or holders of 25% of the aggregate principal amount of the Notes of that series; • An event of default under any indenture or instrument evidencing or under which Quest Diagnostics or any Subsidiary Guarantor then has outstanding any Indebtedness shall occur and be
continuing and either:
(1)
such event of default results from the failure to pay the principal of such Indebtedness in excess of $200 million at final maturity of such Indebtedness, individually or in the aggregate; or (2) as a result of such event of default the maturity of such Indebtedness shall have been accelerated so that the same shall be or become due and payable prior to the date on which the same
would otherwise have become due and payable and the principal amount of such Indebtedness, together with the principal of any other Indebtedness of Quest Diagnostics or such
Subsidiary Guarantor in default, or the maturity of which has been accelerated, aggregates at least $200 million, individually or in the aggregate;
•
Any Subsidiary Guarantor repudiates its obligations under its guarantee of the Notes or, other than by reason of the termination of the Indenture or the release of any such guarantee in
accordance with the Indenture, any such guarantee ceases to be in full force and effect or is declared null and void and such condition shall have continued for a period of 30 days after written
notice of such failure requiring Quest Diagnostics or the Subsidiary Guarantor to remedy the same shall have been given to Quest Diagnostics by the trustee or to Quest Diagnostics and the
trustee by the holders of 25% in aggregate principal amount of the Notes then outstanding; or • Quest Diagnostics or any Subsidiary Guarantor files for bankruptcy or certain other events of bankruptcy, insolvency or reorganization occur. The trustee may withhold notice to the holders of Notes of any default (except in the payment of principal or interest) if it considers such withholding of notice to be in the best interests of the
holders. If an event of default with respect to the Notes of either series has occurred and has not been cured, the trustee or the holders of 25% in aggregate principal amount of the Notes of that series
may declare the entire principal amount (and premium, if any) of, and all the accrued interest on the Notes of that series to be due and immediately payable. This is called a declaration of
acceleration of maturity. If an event of default with respect to the Notes of either series occurs because of certain events in bankruptcy, insolvency or reorganization, the principal amount of the S-33
•
Notes of that series will be automatically accelerated, without any action by the trustee or any holder. Holders of a majority in principal amount of the Notes of either series may also waive certain
past defaults under the Indenture on behalf of all of the holders of the Notes of that series. A declaration of acceleration of maturity with respect to the Notes of either series may be canceled, under
specific circumstances, by the holders of at least a majority in principal amount of the Notes of that series. Except in cases of default, where the trustee has some special duties, the trustee is not required to take any action under the Indenture at the request of any of the holders unless the holders
offer the trustee protection reasonably satisfactory to it from expenses and liability called an “indemnity.” If indemnity reasonably satisfactory to the trustee is provided, the holders of a majority in
principal amount of the Notes of either series may, with respect to the Notes of that series, direct the time, method and place of conducting any lawsuit or other formal legal action seeking any
remedy available to the trustee. The trustee may refuse to follow those directions in certain circumstances. No delay or omission in exercising any right or remedy will be treated as a waiver of the
right, remedy or event of default. Before you are allowed to bypass the trustee and bring a lawsuit or other formal legal action or take other steps to enforce your rights or protect your interests relating to the Notes of either
series, the following must occur:
•
You must give the trustee written notice that an event of default has occurred and remains uncured; • The holders of at least 25% in principal amount of the outstanding Notes of that series must make a written request that the trustee take action because of the default and must offer the
trustee indemnity reasonably satisfactory to it against the cost and other liabilities of taking that action; • The trustee must not have taken action for 60 days after receipt of the above notice and offer of indemnity; and • Holders of a majority in principal amount of the Notes of that series must not have given the trustee a direction inconsistent with the above notice. However, you are entitled at any time to bring a lawsuit for the payment of money due on your Notes on or after the due date. Defeasance Full Defeasance. If there is a change in federal tax law, as described below, we can legally release ourselves and our Subsidiary Guarantors from any payment or other obligations on the Notes,
called “full defeasance,” if we put in place the following other arrangements for you to be repaid:
•
We must deposit in trust for your benefit and the benefit of all other registered holders of the Notes a combination of money and U.S. government or U.S. government agency notes or bonds
that will generate enough cash to make interest, principal and any other payments on the Notes on their various due dates including, possibly, their earliest redemption date. • In order for us to effect a full defeasance, we must deliver to the trustee a legal opinion confirming that you will not recognize income, gain or loss for United States federal income tax
purposes as a result of the defeasance and that you will not be taxed on the Notes any differently than if the defeasance had not occurred. If we accomplish full defeasance, as described above, you would have to rely solely on the trust deposit for repayment on the Notes. You could not look to us or our Subsidiary Guarantors for
repayment in the unlikely event of any shortfall. Conversely, the trust deposit would most likely be protected from claims of our lenders and other creditors if we ever become bankrupt or insolvent. Covenant Defeasance. Under current federal tax law, we can make the same type of deposit described above and be released and cause our Subsidiary Guarantors to be released from the
restrictive covenants in the Notes, if any. This is called “covenant defeasance.” In that event, you S-34
would lose the protection of those restrictive covenants but would gain the protection of having money and securities set aside in trust to repay the Notes. In order to achieve covenant defeasance,
we must do the following:
•
We must deposit in trust for your benefit and the benefit of all other registered holders of the Notes a combination of money and U.S. government or U.S. government agency notes or bonds
that will generate enough cash to make interest, principal and any other payments on the Notes on their various due dates. • We must deliver to the trustee a legal opinion confirming that under current United States federal income tax law you will not recognize income, gain or loss for United Sates federal income
tax purposes as a result of the covenant defeasance and that you will not be taxed on the Notes any differently than if the covenant defeasance had not occurred. If we accomplish covenant defeasance, the following provisions of the Indenture and the Notes would no longer apply unless otherwise specified:
•
any promises of our Subsidiary Guarantors relating to their guarantees, the conduct of their business and any other covenants applicable to the series of Notes; • our promises regarding conduct of our business and other matters and any other covenants applicable to the series of Notes; and • the definition of an event of default as a breach of such covenants. If we accomplish covenant defeasance, you can still look to us and our Subsidiary Guarantors for repayment of the Notes if there were a shortfall in the trust deposit. In fact, if one of the
remaining events of default occurred (such as our bankruptcy) and the Notes become immediately due and payable, there may be such a shortfall. Depending on the event causing the default, of
course, you may not be able to obtain payment of the shortfall. In order to exercise either full defeasance or covenant defeasance, we must comply with certain conditions, and no event or condition can exist that would prevent us and our Subsidiary
Guarantors from making payments of principal, premium, and interest, if any, on the Notes of such series on the date the irrevocable deposit is made or at any time during the period ending on the
91st day after the deposit date. Notices With respect to the Notes, we and the trustee will send notices regarding the Notes only to registered holders, using their addresses as listed in the list of registered holders. Global Notes: Book-Entry System The Global Notes The Notes of each series will be represented by one or more fully registered global notes, without interest coupons and will be deposited upon issuance with the trustee as custodian for The
Depository Trust Company, New York, New York (“DTC”), and registered in the name of DTC or its nominee, in each case, for credit to an account of a direct or indirect participant as described
below. Except as set forth below, the global notes may be transferred, in whole and not in part, only to another nominee of DTC or to a successor of DTC or its nominee. Beneficial interests in the
global notes may not be exchanged for definitive notes in registered certificated form (“certificated notes”) except in the limited circumstances described below. See “—Certain Book-Entry Procedures
for the Global Notes.” Except in the limited circumstances described below, owners of beneficial interests in the global notes will not be entitled to receive physical delivery of notes in certificated form. Transfers of beneficial interests in the global notes are subject to the applicable rules and procedures of DTC and its direct or indirect participants, which may change. S-35
The Notes may be presented for registration of transfer and exchange at the offices of the trustee. Certain Book-Entry Procedures for the Global Notes All interests in the global notes will be subject to the operations and procedures of DTC, Euroclear and Clearstream Luxembourg. The descriptions of the operations and procedures of DTC,
Euroclear and Clearstream Luxembourg set forth below are provided solely as a matter of convenience. These operations and procedures are solely within the control of the respective settlement
systems and are subject to change by them from time to time. We obtained the information in this section and elsewhere in this prospectus supplement concerning DTC, Euroclear and Clearstream
Luxembourg and their respective book-entry systems from sources that we believe are reliable, but we take no responsibility for the accuracy of any of this information, and investors are urged to
contact the relevant system or its participants directly to discuss these matters. DTC. DTC has advised us that it is:
•
a limited-purpose trust company organized under the laws of the State of New York; • a “banking organization” within the meaning of the New York State Banking Law; • a member of the Federal Reserve System; • a “clearing corporation” within the meaning of the New York Uniform Commercial Code, as amended; and • a “clearing agency” registered pursuant to Section 17A of the Exchange Act. DTC was created to hold securities for its participants (collectively, the “participants”) and to facilitate the clearance and settlement of securities transactions between its participants through
electronic book-entry changes to the accounts of its participants, thereby eliminating the need for physical transfer and delivery of certificates. DTC’s participants include securities brokers and dealers
(including some or all of the underwriters), banks and trust companies, clearing corporations and certain other organizations. Indirect access to DTC’s system is also available to other entities such as
Clearstream Luxembourg, Euroclear, banks, brokers, dealers and trust companies (collectively, the “indirect participants”) that clear through or maintain a custodial relationship with a participant,
either directly or indirectly. Investors who are not participants may beneficially own securities held by or on behalf of DTC only through participants or indirect participants in DTC. Clearstream Luxembourg. Clearstream Luxembourg is incorporated under the laws of Luxembourg as a professional depositary. Clearstream Luxembourg holds securities for its participating
organizations (“Clearstream Luxembourg Participants”) and facilitates the clearance and settlement of securities transactions between Clearstream Luxembourg Participants through electronic book-
entry changes in accounts of Clearstream Luxembourg Participants, thereby eliminating the need for physical movement of certificates. Clearstream Luxembourg provides Clearstream Luxembourg
Participants with, among other things, services for safekeeping, administration, clearance and establishment of internationally traded securities and securities lending and borrowing. Clearstream
Luxembourg interfaces with domestic markets in several countries. As a professional depositary, Clearstream Luxembourg is subject to regulation by the Luxembourg Monetary Institute. Clearstream
Luxembourg Participants are recognized financial institutions around the world, including underwriters, securities brokers and dealers, banks, trust companies, clearing corporations and certain other
organizations, and may include the underwriters. Indirect access to Clearstream Luxembourg is also available to others, such as banks, brokers, dealers and trust companies that clear through or
maintain a custodial relationship with a Clearstream Luxembourg Participant either directly or indirectly. Distributions with respect to Notes held beneficially through Clearstream Luxembourg will be credited to cash accounts of Clearstream Luxembourg Participants in accordance with its rules and
procedures to the extent received by the U.S. depositary for Clearstream Luxembourg. Euroclear. Euroclear was created in 1968 to hold securities for participants of Euroclear (“Euroclear Participants”) and to clear and settle transactions between Euroclear Participants S-36
through simultaneous electronic book-entry delivery against payment, thereby eliminating the need for physical movement of certificates and any risk from lack of simultaneous transfers of securities
and cash. Euroclear includes various other services, including securities lending and borrowing and interfaces with domestic markets in several markets in several countries. Euroclear is operated by
Euroclear Bank S.A./N.V. (the “Euroclear Operator”), under contract with Euro-clear Clearance Systems S.C., a Belgian cooperative corporation (the “Cooperative”). All operations are conducted by
the Euroclear Operator, and all Euroclear securities clearance accounts and Euroclear cash accounts are accounts with the Euroclear Operator, not the Cooperative. The Cooperative establishes policy
for Euroclear on behalf of Euroclear Participants. Euroclear Participants include banks (including central banks), securities brokers and dealers and other professional financial intermediaries and may
include the underwriters. Indirect access to Euroclear is also available to other firms that clear through or maintain a custodial relationship with a Euroclear Participant, either directly or indirectly. The Euroclear Operator is regulated and examined by the Belgian Banking Commission. Distributions of principal and interest with respect to Notes held through Euroclear or Clearstream
Luxembourg will be credited to the cash accounts of Euroclear or Clearstream Luxembourg participants in accordance with the relevant system’s rules and procedures, to the extent received by such
system’s depositary. Links have been established among DTC, Clearstream Luxembourg and Euroclear to facilitate the initial issuance of the Notes and cross-market transfers of the Notes associated with secondary
market trading. DTC will be linked indirectly to Clearstream Luxembourg and Euroclear through the DTC accounts of their respective U.S. depositaries. Book-Entry Procedures. We expect that, pursuant to procedures established by DTC:
•
upon deposit of each global note, DTC will credit, on its book-entry registration and transfer system, the accounts of participants designated by the underwriters with an interest in that global
note; and • ownership of beneficial interests in the global notes will be shown on, and the transfer of ownership interests in the global notes will be effected only through, records maintained by DTC (with
respect to the interests of participants) and by participants and indirect participants (with respect to the interests of persons other than participants). The laws of some jurisdictions may require that some purchasers of Notes take physical delivery of those Notes in definitive form. Accordingly, the ability to transfer beneficial interests in notes
represented by a global note to those persons may be limited. In addition, because DTC can act only on behalf of its participants, who in turn act on behalf of persons who hold interests through
participants, the ability of a person holding a beneficial interest in a global note to pledge or transfer that interest to persons or entities that do not participate in DTC’s system, or to otherwise take
actions in respect of that interest, may be affected by the lack of a physical note in respect of that interest. So long as DTC or its nominee is the registered owner of a global note, DTC or that nominee, as the case may be, will be considered the sole legal owner or holder of the notes represented by
that global note for all purposes of the Notes and the Indenture. Except as provided below, owners of beneficial interests in a global note (1) will not be entitled to have the Notes represented by
that global note registered in their names, (2) will not receive or be entitled to receive physical delivery of certificated notes, and (3) will not be considered the owners or holders of the Notes
represented by that beneficial interest under the indenture for any purpose, including with respect to the giving of any direction, instruction or approval to the trustee. Accordingly, each holder
owning a beneficial interest in a global note must rely on the procedures of DTC and, if that holder is not a participant or an indirect participant, on the procedures of the participant through which
that holder owns its interest, to exercise any rights of a holder of Notes under the Indenture or that global note. We understand that under existing industry practice, in the event that we request any
action of holders of notes, or a holder that is an owner of a beneficial interest in a global note desires to take any action that DTC, as the holder of that global note, is entitled to take, DTC would
authorize the participants to take that action and the participants would authorize holders owning through those S-37
participants to take that action or would otherwise act upon the instruction of those holders. Neither we nor the Trustee will have any responsibility or liability for any aspect of the records relating
to or payments made on account of notes by DTC, or for maintaining, supervising or reviewing any records of DTC relating to the Notes. Payments with respect to the principal of and interest on a global note will be payable by the trustee to or at the direction of DTC or its nominee in its capacity as the registered holder of the
global note under the Indenture. Under the terms of the Indenture, we and the trustee may treat the persons in whose names the Notes, including the global notes, are registered as the owners
thereof for the purpose of receiving payment thereon and for any and all other purposes whatsoever. Accordingly, neither we nor the trustee has or will have any responsibility or liability for the
payment of those amounts to owners of beneficial interests in a global note. Payments by the participants and the indirect participants to the owners of beneficial interests in a global note will be
governed by standing instructions and customary industry practice and will be the responsibility of the participants and indirect participants and not of DTC. Transfers between participants in DTC will be effected in accordance with DTC’s procedures, and will be settled in same-day funds. Transfers between participants in Euroclear or Clearstream
Luxembourg will be effected in the ordinary way in accordance with their respective rules and operating procedures. Cross-market transfers between the participants in DTC, on the one hand, and Euroclear or Clearstream Luxembourg participants, on the other hand, will be effected through DTC in accordance
with DTC’s rules on behalf of Euroclear or Clearstream Luxembourg, as the case may be, by its respective depositary. However, those cross-market transactions will require delivery of instructions to
Euroclear or Clearstream Luxembourg, as the case may be, by the counterparty in that system in accordance with the rules and procedures and within the established deadlines (Brussels time) of that
system. Euroclear or Clearstream Luxembourg, as the case may be, will, if the transaction meets its settlement requirements, deliver instructions to its respective depositary to take action to effect
final settlement on its behalf by delivering or receiving interests in the relevant global notes in DTC, and making or receiving payment in accordance with normal procedures for same-day funds
settlement applicable to DTC. Euroclear participants and Clearstream Luxembourg participants may not deliver instructions directly to the depositaries for Euroclear or Clearstream Luxembourg. Although we understand that DTC, Euroclear and Clearstream Luxembourg have agreed to the foregoing procedures to facilitate transfers of interests in the global notes among participants in
DTC, Euroclear and Clearstream Luxembourg, they are under no obligation to perform or to continue to perform those procedures, and those procedures may be discontinued at any time. Neither
we nor the trustee will have any responsibility for the performance by DTC, Euroclear or Clearstream Luxembourg or their respective participants or indirect participants of their respective
obligations under the rules and procedures governing their operations. Same-Day Settlement and Payment We will make payments in respect of the Notes represented by the global notes (including principal and interest) by wire transfer of immediately available funds to the accounts specified by the
global note holder. We will make all payments of principal and interest with respect to certificated notes by wire transfer of immediately available funds to the accounts specified by the holders of the
certificated notes or, if no such account is specified, by mailing a check to each such holder’s registered address. The notes represented by the global notes are expected to trade in DTC’s Same-Day
Funds Settlement System. Because of time zone differences, the securities account of a Euroclear or Clearstream Luxembourg participant purchasing an interest in a global note from a participant in DTC will be credited,
and any such crediting will be reported to the relevant Euroclear or Clearstream Luxembourg participant, during the securities settlement processing day (which must be a business day for Euroclear
and Clearstream Luxembourg) immediately following the settlement date of DTC. DTC has advised us that cash received in Euroclear or Clearstream Luxembourg as a result of sales S-38
of interests in a global note by or through a Euroclear or Clearstream Luxembourg participant to a participant in DTC will be received with value on the settlement date of DTC but will be
available in the relevant Euroclear or Clearstream Luxembourg cash account only as of the business day for Euroclear or Clearstream Luxembourg following DTC’s settlement date. None of Quest Diagnostics, any underwriter or agent, the trustee or any applicable paying agent will have any responsibility or liability for any aspect of the records relating to or payments made
on account of beneficial interests in a global note, or for maintaining, supervising or reviewing any records. Modification or Waiver There are three types of changes we can make to the Indenture and the Notes. Changes Requiring Your Approval. First, there are changes that cannot be made to your Notes without your specific approval. Following is a list of those types of changes:
•
changing the stated maturity of the principal of or interest on the Notes; • reducing any amounts due on the Notes or payable upon acceleration of the maturity of the security following a default; • adversely affecting any right of repayment at the holder’s option; • changing the place (except as otherwise described in this prospectus supplement) or currency of payment on the Notes; • impairing your right to sue for payment or to convert or exchange Notes; • modifying the Notes to subordinate the Notes to other indebtedness; • reducing the percentage of holders of Notes whose consent is needed to modify or amend the Indenture; • reducing the percentage of holders of Notes whose consent is needed to waive compliance with certain provisions of the Indenture or to waive certain defaults; • reducing the requirements for quorum or voting with respect to the Notes; • modifying any other aspect of the provisions of the Indenture dealing with modification and waiver except to increase the voting requirements; and • change in any of our obligations to pay additional amounts to holders with respect to taxes imposed on such holders in certain circumstances. Changes Requiring a Majority Vote. The second type of change to the Indenture and the outstanding Notes is the kind that requires a vote in favor by holders of outstanding Notes owning a
majority of the principal amount of Notes. Most changes fall into this category, except for clarifying changes and certain other changes that would not adversely affect holders of the outstanding
Notes in any material respect. The same vote would be required for us and our Subsidiary Guarantors to obtain a waiver of all or part of certain covenants in the Indenture, or a waiver of a past
default. However, we and our Subsidiary Guarantors cannot obtain a waiver of a payment default or any other aspect of the Indenture or the outstanding Notes listed in the category described
previously under “—Changes Requiring Your Approval” unless we and our Subsidiary Guarantors obtain your individual consent to the waiver. Changes Not Requiring Approval. The third type of change does not require any vote by holders of outstanding Notes. This type is limited to clarifications, curing ambiguities, defects or
inconsistencies and certain other changes that would not adversely affect holders of the outstanding Notes in any material respect. Qualifying or maintaining the qualification of the Indenture under
the Trust Indenture Act does not require any vote by holders of Notes. S-39
Satisfaction and Discharge The Indenture will cease to be of further effect, and we and our Subsidiary Guarantors will be deemed to have satisfied and discharged the Indenture with respect to the Notes, when the
following conditions have been satisfied:
•
all Notes not previously delivered to the trustee for cancellation have become due and payable or will become due and payable at their stated maturity or on a redemption date within one
year; • we deposit with the trustee, in trust, funds sufficient to pay the entire indebtedness on the Notes that had not been previously delivered for cancellation, for the principal and interest to the
date of the deposit (for Notes that have become due and payable) or to the stated maturity or the redemption date, as the case may be (for Notes that have not become due and payable); • we have paid or caused to be paid all other sums payable under the Indenture; and • we have delivered to the trustee an officer’s certificate and opinion of counsel, each stating that all these conditions have been complied with. We will remain obligated to provide for registration of transfer and exchange and to provide notices of redemption. The Trustee The trustee will be The Bank of New York. The Bank of New York also will be the initial paying agent and registrar for the Notes. The Bank of New York is also the trustee and note registrar
for our 5.125% senior notes due 2010, our 7.5% senior notes due 2011 and our 5.45% senior notes due 2015. The Indenture provides that, except during the continuance of an event of default under the Indenture, the trustee under the Indenture will perform only such duties as are specifically set forth
in the Indenture. Under the Indenture, the holders of a majority in outstanding principal amount of the Notes will have the right to direct the time, method and place of conducting any proceeding or
exercising any remedy available to the trustee under the Indenture, subject to certain exceptions. If an event of default has occurred and is continuing, the trustee under the Indenture will exercise
such rights and powers vested in it under the Indenture and use the same degree of care and skill in its exercise as a prudent person would exercise under the circumstances in the conduct of such
person’s own affairs. The Indenture and provisions of the Trust Indenture Act incorporated by reference in the Indenture contain limitations on the rights of the trustee under such Indenture, should it become a
creditor of our company, to obtain payment of claims in certain cases or to realize on certain property received by it in respect of any such claims, as security or otherwise. The trustee under the
Indenture is permitted to engage in other transactions. However, if the trustee under the Indenture acquires any prohibited conflicting interest, it must eliminate the conflict or resign. The trustee may resign or be removed and a successor trustee may be appointed. Governing Law The Indenture and the Notes will be governed by, and construed in accordance with, the laws of the State of New York without application of principles of conflicts of law thereunder. Definitions The following definitions are applicable to this Description of Notes: “Acquired Indebtedness” means Indebtedness of a Person (1) existing at the time such Person becomes a Restricted Subsidiary or (2) assumed in connection with the acquisition of assets by such
Person, in each case, other than Indebtedness incurred in connection with, or in contemplation of, such Person becoming a Restricted Subsidiary or such acquisition, as the case may be. S-40
“Attributable Debt” means, with respect to a Sale and Leaseback Transaction, an amount equal to the lesser of: (1) the fair market value of the property (as determined in good faith by our
board of directors); and (2) the present value of the total net amount of rent payments to be made under the lease during its remaining term, discounted at the rate of interest set forth or implicit in
the terms of the lease, compounded semi-annually. The calculation of the present value of the total net amount of rent payments is subject to adjustments specified in the Indenture. “Capitalized Lease” means any obligation of a Person to pay rent or other amounts incurred with respect to real property or equipment acquired or leased by such Person and used in its
business that is required to be recorded as a capital lease in accordance with generally accepted accounting principles. “Consolidated Total Assets” means, with respect to any Person as of any date, the amount of total assets as shown on the consolidated balance sheet of such Person for the most recent fiscal
quarter for which financial statements have been filed with the Securities and Exchange Commission, prepared in accordance with accounting principles generally accepted in the United States. “Existing Receivables Credit Facility” means the receivables-backed financing transaction pursuant to (1) the Second Amended and Restated Receivables Sales Agreement, dated as of April 20,
2004 between Quest Diagnostics and each of its direct and indirect wholly owned Subsidiaries that is a seller thereunder, and Quest Diagnostics Receivables Inc., as the buyer, (2) the Third Amended
and Restated Credit and Security Agreement, dated as of April 20, 2004, as amended, among Quest Diagnostics Receivables Inc., as borrower, Quest Diagnostics, as initial servicer, each of the
lenders from time to time party thereto, and Wachovia Bank, N.A., as administrative agent, and (3) the various related ancillary documents. “Indebtedness” of any Person means, without duplication (1) any obligation of such Person for money borrowed, (2) any obligation of such Person evidenced by bonds, debentures, notes or other
similar instruments, (3) any reimbursement obligation of such Person in respect of letters of credit or other similar instruments which support financial obligations which would otherwise become
Indebtedness, and (4) any obligation of such Person under Capitalized Leases; provided, however, that “Indebtedness” of such Person shall not include any obligation of such Person to any Subsidiary
of such Person or to any Person with respect to which such Person is a Subsidiary. “Initial Subsidiary Guarantors” means each of American Medical Laboratories Incorporated, AmeriPath Consolidated Labs, Inc., AmeriPath Florida, LLC, AmeriPath Hospital Services Florida,
LLC, AmeriPath Indiana, LLC, AmeriPath Kentucky, Inc., AmeriPath Marketing USA, Inc., AmeriPath Michigan, Inc., AmeriPath Mississippi, Inc., AmeriPath New York, LLC, AmeriPath North
Carolina, Inc., AmeriPath Ohio, Inc., AmeriPath Pennsylvania, LLC, AmeriPath Philadelphia, Inc., AmeriPath SC, Inc., AmeriPath Texas, LP, AmeriPath Wisconsin, LLC, AmeriPath Youngstown
Labs, Inc., AmeriPath, Inc., AmeriPath, LLC, AML Inc., Anatomic Pathology Services, Inc., API No. 2, LLC, APL Properties Limited Liability Company, Arizona Pathology Group, Inc., Central
Plains Holdings, Inc., Central Plains Laboratories, LLC, Dermatopathology Services, Inc., Diagnostic Pathology Management Services, LLC, Diagnostic Reference Services Inc., DPD Holdings, Inc.,
Enterix Inc., ExamOne World Wide of NJ, Inc., ExamOne World Wide, Inc., FNA Clinics of America, Inc. (f/k/a Unilab Acquisition Corporation), Focus Diagnostics, Inc., Focus Technologies
Holding Company, HemoCue, Inc., Kailash B. Sharma, M.D., Inc., LabOne of Ohio, Inc., LabOne, Inc., MetWest Inc., Nichols Institute Diagnostics, Ocmulgee Medical Pathology Association, Inc.,
O’Quinn Medical Pathology Association, LLC, Osborn Group Inc., Pathology Building Partnership, PCA of Denver, Inc., PCA of Nashville, Inc., Peter G. Klacsmann, M.D., Inc., Quest Diagnostics
Clinical Laboratories, Inc., Quest Diagnostics Finance Incorporated, Quest Diagnostics Holdings Incorporated, Quest Diagnostics Incorporated (MD), Quest Diagnostics Incorporated (MI), Quest
Diagnostics Incorporated (NV), Quest Diagnostics Investments Incorporated, Quest Diagnostics LLC (CT), Quest Diagnostics LLC (IL), Quest Diagnostics LLC (MA), Quest Diagnostics Nichols
Institute (f/k/a Quest Diagnostics Incorporated (CA)), Quest Diagnostics Nichols Institute, Inc., Quest Diagnostics of Pennsylvania Inc., Regional Pathology Consultants, LLC, Rocky Mountain
Pathology, LLC, Sharon G. Daspit, M.D., Inc., Shoals Pathology S-41
Associates, Inc., Specialty Laboratories, Inc., Strigen, Inc., Systematic Business Services, Inc., TID Acquisition Corp., Unilab Corporation. “Lien” means any pledge, mortgage, lien, encumbrance or other security interest. “Officer’s Certificate” means a certificate signed by any Officer of Quest Diagnostics or any Subsidiary Guarantor, as the case may be, in his or her capacity as such Officer and delivered to the
trustee. “Permitted Acquired Indebtedness” means any Acquired Indebtedness that remains outstanding following the expiration of a good faith offer by Quest Diagnostics or the Subsidiary of Quest
Diagnostics obligated under such Acquired Indebtedness to acquire such Acquired Indebtedness, including, without limitation, an offer to exchange such Acquired Indebtedness for debt securities of
Quest Diagnostics, on terms, which in the opinion of an independent investment banking firm of national reputation and standing, are consistent with market practices in existence at the time for
offers of a similar nature; provided that the initial expiration date of any such offer shall be not later than the expiration of the 270-day period referred to in the first paragraph of the “Limitation on
Subsidiary Indebtedness and Preferred Stock” covenant; provided further that the amount of Acquired Indebtedness that shall constitute “Permitted Acquired Indebtedness” shall only be equal to the
amount of Acquired Indebtedness that Quest Diagnostics or such Subsidiary has made an offer to acquire in accordance with the foregoing. “Person” means any individual, corporation, limited liability company, partnership, joint venture, association, joint stock company, trust, unincorporated organization or government or any agency
or political subdivision thereof or other similar entity. “Preferred Stock” means, with respect to any Person, any and all shares of preferred stock (however designated) issued by such Person, that is entitled to preference or priority over one or more
series or classes of capital stock issued by such Person upon any distribution of such Person’s property and assets, whether by dividend or on liquidation, whether now outstanding, or issued after the
date that the Notes are issued. “Principal Property” means any real property and any related buildings, fixtures or other improvements located in the United States owned by Quest Diagnostics or its Subsidiaries (1) on or in
which one of its 30 largest domestic clinical laboratories conducts operations, as determined by net revenues for the four most recent fiscal quarters for which financial statements have been filed with
the Securities and Exchange Commission, or (2) the net book value of which at the time of the determination exceeds 1% of the Consolidated Total Assets of Quest Diagnostics. As of the date of
this prospectus supplement, Quest Diagnostics and its Subsidiaries owned 13 of the 30 largest domestic clinical laboratories operated by Quest Diagnostics and its Subsidiaries. These 13 owned
domestic clinical laboratories are “Principal Properties” under the above definition. “Receivables Credit Facility” means any receivables-backed financing transaction including the Existing Receivables Credit Facility, in each case as such transaction may be amended or otherwise
modified from time to time or refinanced or replaced with respect to all or any portion of the indebtedness under such transaction. “Restricted Subsidiary” means any Subsidiary of Quest Diagnostics that owns a Principal Property. “Sale and Leaseback Transaction” means any arrangement with any person providing for the leasing by Quest Diagnostics or any Restricted Subsidiary of any Principal Property that has been or
is to be sold or transferred by Quest Diagnostics or any Restricted Subsidiary to such person, as the case may be. “Specified Subsidiaries” means AmeriPath Group Holdings, Inc., AmeriPath Holdings, Inc., AmeriPath Intermediate Holdings, Inc. and MedPlus, Inc. “Subsidiary” of any Person means (1) a corporation, a majority of the outstanding voting stock of which is, at the time, directly or indirectly, owned by such Person by one or more Subsidiaries
of such Person, or by such Person and one or more Subsidiaries thereof or (2) any other Person (other than a corporation), including, without limitation, a partnership or joint venture, in which such S-42
Person, one or more Subsidiaries thereof or such Person and one or more Subsidiaries thereof, directly or indirectly, at the date of determination thereof, has at least majority ownership interest
entitled to vote in the election of directors, managers or trustees thereof (or other Person performing similar functions). “Subsidiary Guarantors” means, at any time, (1) each Initial Subsidiary Guarantor and (2) each existing and future domestic Subsidiary of Quest Diagnostics which is required to guarantee the
obligations of Quest Diagnostics under the Notes, provided that, in each case, such Initial Subsidiary Guarantor or such other domestic Subsidiary continues to guarantee the Notes at such time. S-43
UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS The following discussion is a summary of the material United States federal income tax consequences and, in the case of a non-United States Holder (as defined below), the material United
States federal estate tax consequences, relevant to the purchase, ownership and disposition of the Notes, but does not purport to be a complete analysis of all potential tax effects. The discussion is
based upon the Internal Revenue Code of 1986, as amended (the “Code”), United States Treasury Regulations issued thereunder, Internal Revenue Service (“IRS”) rulings and pronouncements and
judicial decisions now in effect, all of which are subject to change at any time. Any such change may be applied retroactively in a manner that could adversely affect a beneficial owner of the Notes.
This discussion does not address all of the United States federal income tax consequences that may be relevant to a beneficial owner of the Notes in light of its particular circumstances or to
beneficial owners of the Notes subject to special rules, such as certain financial institutions, U.S. expatriates, insurance companies, dealers in securities or foreign currencies, traders in securities,
“United States Holders” (as defined below) whose functional currency is not the U.S. dollar, partnerships and other pass through entities and their beneficial owners, tax-exempt organizations and
persons holding the notes as part of a “straddle,” “hedge,” “conversion transaction” or other integrated transaction. In addition, this discussion is limited to beneficial owners of the Notes that
purchase the Notes for cash in this offering at a price equal to their “issue price” within the meaning of Section 1273 of the Code. Moreover, the effect of any applicable state, local or foreign tax
laws is not discussed. The discussion deals only with Notes held as “capital assets” within the meaning of Section 1221 of the Code. As used in this prospectus supplement, “United States Holder” means a beneficial owner of the Notes that is for United States federal income tax purposes:
•
a citizen or resident alien individual of the United States; • a corporation or other entity taxable as a corporation created or organized in or under the laws of the United States, any State thereof or the District of Columbia; • an estate the income of which is subject to United States federal income tax regardless of its source; or • a trust, if a United States court can exercise primary supervision over the administration of the trust and one or more United States persons can control all substantial trust decisions, or if the
trust was in existence on August 20, 1996 and has elected to continue to be treated as a United States person. A “non-United States Holder” is a beneficial owner of Notes that is neither a United States Holder nor a partnership or other entity treated as a partnership for United States federal income tax
purposes. If a beneficial owner of the Notes is a partnership or other entity treated as a partnership for United States federal income tax purposes, the tax treatment of the partnership and each partner in
such partnership generally will depend on the activities of the partnership and the status of the partner. Partnerships that hold Notes, and partners in such partnerships, should consult their own tax
advisors. Prospective investors should consult their own tax advisors with regard to the application of the tax consequences discussed below to their particular situations as well as the application of any
state, local, foreign or other tax laws, including gift and estate tax laws. United States Holders Interest Payments of stated interest on the Notes will be taxable to a United States Holder as ordinary income at the time that such payments are received or accrued, in accordance with such United
States Holder’s regular method of accounting for United States federal income tax purposes. S-44
Sale or Other Taxable Disposition of the Notes A United States Holder will recognize gain or loss on the sale, exchange (including, in certain circumstances, a deemed exchange as a result of an assumption by any Person of our obligations
under the Notes and the Indenture as described under “Description of Notes—Merger, Consolidation or Sale of Assets”), redemption, retirement or other taxable disposition of a Note in an amount
equal to the difference between the amount realized upon the disposition (less any portion allocable to any accrued and unpaid interest, which will be taxable as ordinary interest income to the extent
not previously included in gross income) and the United States Holder’s tax basis in the Note. Such gain or loss generally will be a capital gain or loss, and will be a long-term capital gain or loss if
the United States Holder has held the Note for more than one year at the time of the disposition. A United States Holder’s tax basis in a Note generally will be the price such holder paid for the
Note. Long-term capital gains of individuals generally are eligible for reduced rates of United States federal income tax. The deductibility of capital losses is subject to limitations under the Code. Backup Withholding A United States Holder may be subject to backup withholding tax, currently at a 28% rate, when such holder receives interest and principal payments on the Notes, or upon the proceeds
received from the sale or other disposition of such Notes. Certain United States Holders (including, among others, corporations and certain tax-exempt organizations) generally are exempt from
backup withholding. A non-exempt United States Holder will be subject to this backup withholding tax if such holder:
•
fails to furnish its taxpayer identification number (“TIN”), which, for an individual, ordinarily is his or her social security number; • furnishes an incorrect TIN; • is notified by the IRS that the United States Holder has failed to properly report payments of interest or dividends; or • fails to certify, under penalties of perjury, that the United States Holder is a United States person, has furnished a correct TIN and that the IRS has not notified the United States Holder that
it is subject to backup withholding. United States Holders should consult their personal tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption, if
applicable. The backup withholding tax is not an additional tax and United States Holders may use amounts withheld as a refund or credit against their United States federal income tax liability so
long as the requisite information is timely furnished to the IRS. Non-United States Holders Interest Payments and Gains from Dispositions Interest paid to a non-United States Holder generally will not be subject to United States federal income tax, and United States federal withholding tax of 30% (or, if applicable, a lower treaty
rate) will not apply, provided:
•
such holder does not directly or indirectly, actually or constructively, own 10% or more of our voting stock; • such holder is not a controlled foreign corporation that is related to us through sufficient stock ownership and is not a bank that receives the interest on an extension of credit made pursuant to
a loan agreement entered into in the ordinary course of its trade or business; • such interest is not effectively connected with a trade or business conducted by the non-United States Holder within the United States (or, if an income tax treaty applies, is not attributable to
a United States “permanent establishment” maintained by the non-United States Holder); and S-45
• either (1) the non-United States Holder certifies to us or our paying agent, under penalties of perjury, that it is not a “United States person” within the meaning of the Code and provides its
name and address, or (2) a securities clearing organization, bank or other financial institution that holds customers’ securities in the ordinary course of its trade or business and holds the Notes
on behalf of the non-United States Holder certifies to us or our paying agent under penalties of perjury that it, or the financial institution between it and the non-United States Holder, has
received from the non-United States Holder a statement, under penalties of perjury, that such non-United States Holder is not a “United States person” and provides us or our paying agent
with a copy of this statement. If you cannot satisfy the requirements described above, payments of interest made to you will be subject to the 30% United States federal withholding tax, unless you provide us or our paying
agent with a properly executed (1) IRS Form W-8BEN (or other applicable form) claiming an exemption from or reduction in withholding under the benefit of an applicable tax treaty or (2) IRS
Form W-8ECI (or other applicable form) stating that interest paid on your Note is not subject to withholding tax because it is effectively connected with your conduct of a trade or business in the
United States. The certification requirement described above may require a non-United States Holder that provides an IRS form to also provide its TIN. Prospective investors should consult their tax
advisors regarding the certification requirements for non-United States Holders. A non-United States Holder generally will not be subject to United States federal income or withholding tax on gain and any accrued interest recognized on the sale, exchange, redemption,
retirement or other disposition of a Note unless (1) such gain is effectively connected with a trade or business conducted by the non-United States Holder within the United States (and, if required by
an applicable income tax treaty, is attributable to a United States “permanent establishment” maintained by the non-United States Holder), (2) such holder is an individual who was present in the
United States for 183 days or more in the taxable year of the disposition and certain other conditions are met (in which case, except as otherwise provided by an applicable income tax treaty, such
gain, which may be offset by United States source capital losses, generally will be subject to a flat 30% United States federal income tax, even though the holder is not considered a resident alien
under the Code) or (3) in the case of accrued interest, such accrued interest does not qualify for the exemption from United States federal income tax and United States federal withholding tax
discussed above. If interest on the Notes or gain from a disposition of the Notes is effectively connected with a non-United States Holder’s conduct of a United States trade or business (and, if required by an
applicable income tax treaty, is attributable to a United States “permanent establishment” maintained by the non-United States Holder), the non-United States Holder generally will be subject to
United States federal income tax on the interest or gain on a net basis in the same manner as United States Holders. For effectively-connected interest, the 30% withholding tax described above will
not apply (assuming an appropriate certification is timely provided). A foreign corporation that is a holder of a Note also may be subject to a branch profits tax equal to 30% of its effectively
connected earnings and profits for the taxable year, subject to certain adjustments, unless it qualifies for a lower rate under an applicable income tax treaty. United States Federal Estate Tax If you are an individual and are not a United States citizen or a resident of the United States (as specially defined for United States federal estate tax purposes) at the time of your death, your
Notes generally will not be subject to the United States federal estate tax, unless, at the time of your death:
•
you directly or indirectly, actually or constructively, own 10% or more of our voting stock; or • interest on your Notes is effectively connected with your conduct of a United States trade or business. S-46
Backup Withholding and Information Reporting Backup withholding and information reporting generally will not apply to payments made by us or our paying agents, in their capacities as such, to a non-United States Holder of a Note if the
holder has provided the required certification that it is not a United States person as described above, provided that neither we nor our paying agent has actual knowledge that the holder is a United
States person. However, we or our paying agent may be required to report to the IRS and to non-United States Holders payments of interest on the Notes and the amount of tax, if any, withheld
with respect to those payments. Copies of the information returns reporting such interest payments and any withholding may also be made available to the tax authorities in the country in which such
non-United States Holders reside under the provisions of a treaty or agreement. If a non-United States Holder sells a Note outside the United States through a non-U.S. office of a non-U.S. broker and the sales proceeds are paid to the non-United States Holder outside the
United States, then backup withholding and information reporting generally will not apply to that payment. However, information reporting, but not backup withholding, will apply to a payment of
sales proceeds, even if that payment is made outside the United States, if a non-United States Holder sells a Note through a non-U.S. office of a broker that is:
•
a United States person; • a controlled foreign corporation for United States federal income tax purposes: • a foreign person 50% or more of whose gross income is effectively connected with a United States trade or business for a specified three-year period; or • a foreign partnership, if at any time during its tax year, one or more of its partners are United States persons, as defined in Treasury regulations, who in the aggregate hold more than 50% of
the income or capital interest in the partnership or if, at any time during its tax year, the foreign partnership is engaged in a United States trade or business; unless such broker has documentary evidence in its possession of the non-United States Holder’s foreign status and has no knowledge to the contrary, or the non-United States Holder otherwise
establishes an exemption. Payment of the proceeds from a disposition by a non-United States Holder of a Note made to or through the United States office of a broker will be subject to information reporting and backup
withholding unless the non-United States Holder certifies that it is not a “United States person” or otherwise establishes an exemption from information reporting and backup withholding. Non-United States Holders should consult their own tax advisors regarding application of backup withholding in their particular circumstance and the availability of and procedure for obtaining
an exemption from backup withholding under current Treasury Regulations. Any amounts withheld under the backup withholding rules from a payment to a non-United States Holder will be allowed
as a refund or a credit against the holder’s United States federal income tax liability, provided the required information is timely furnished to the IRS. S-47
Under the terms and subject to the conditions contained in an underwriting agreement dated the date of this prospectus supplement, the underwriters named below for whom Morgan Stanley &
Co. Incorporated, Banc of America Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated are acting as joint book-running managers and representatives, have severally agreed to
purchase, and we have agreed to sell to them, severally, the principal amount of notes indicated in the table below:
Name Principal Amount of 6.40% Senior Notes 6.95% Senior Notes Morgan Stanley & Co. Incorporated $ 131,250,000 $ 148,750,000 Banc of America Securities LLC $ 93,750,000 $ 106,250,000 Merrill Lynch, Pierce, Fenner & Smith $ 93,750,000 $ 106,250,000 Barclays Capital Inc. $ 18,750,000 $ 21,250,000 J.P. Morgan Securities Inc. $ 18,750,000 $ 21,250,000 Wachovia Capital Markets, LLC $ 18,750,000 $ 21,250,000 Total $ 375,000,000 $ 425,000,000 The underwriters are offering the notes subject to their acceptance of the notes from us and subject to prior sale. The underwriting agreement provides that the obligations of the several
underwriters to pay for and accept delivery of the notes offered by this prospectus supplement are subject to the approval of certain legal matters by their counsel and to certain other conditions. The
underwriters are obligated to take and pay for all the notes offered by this prospectus supplement if any such notes are taken. The underwriters initially propose to offer part of the notes directly to the public at the public offering prices set forth on the cover page of this prospectus supplement and part to certain dealers
at a price that represents a concession not in excess of .40% of the principal amount of the 6.40% Senior Notes due 2017 and .50% of the principal amount of the 6.95% Senior Notes due 2037. Any
such dealers may resell any notes purchased from the underwriters to certain other brokers or dealers at a discount not to exceed .20% of the principal amount of the 6.40% Senior Notes due 2017
and .25% of the principal amount of the 6.95% Senior Notes due 2037. After the initial offering of the notes, the offering price and other selling terms may from time to time be varied by the
representatives. The following table shows the per note and total public offering price, underwriting discount, and proceeds before expenses to us.
6.40% Senior Notes
6.95% Senior Notes
Per Note
Total
Per Note
Total Public offering price (1)
99.786
%
$
374,197,500
98.891
%
$
420,286,750 Underwriting discount
0.650
%
$
2,437,500
0.875
%
$
3,718,750 Proceeds, before expenses, to us
99.136
%
$
371,760,000
98.016
%
$
416,568,000
(1)
Plus accrued interest from June 22, 2007, if settlement occurs after that date.
The estimated offering expenses payable by us, exclusive of the underwriting discount, are approximately $0.4 million. In order to facilitate the offering of the notes, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the prices of the notes. Specifically, the underwriters may
over-allot in connection with the offering, creating short positions in the notes for their own account. In addition, to cover over-allotments or to stabilize the prices of the notes, the underwriters may
bid for, and purchase notes on the open market. Finally, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the notes in the offering, if
the syndicate repurchases previously distributed notes in transactions to cover syndicate short positions, S-48
due 2017
due 2037
Incorporated
due 2017
due 2037
in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the notes above independent market levels. The underwriters are not required to engage
in these activities, and may end any of these activities at any time. We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended. Prior to the offering, there have been no active markets for the notes. The underwriters have advised us that certain of the underwriters presently intend to make markets in the notes as
permitted by applicable laws and regulations. Such underwriters are not obligated, however, to make the markets in the notes and any such market making may be discontinued at any time at the
discretion of such underwriters. Accordingly, no assurance can be given as to the liquidity of, or trading markets for, the notes. The prospectus as supplemented by this prospectus supplement in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any,
participating in this offering. The representatives may agree to allocate a number of notes of each series to underwriters for sale to their online brokerage account holders. Internet distributions will
be allocated by the representatives to underwriters that may make Internet distributions on the same basis as other allocations. The underwriters and their affiliates have from time to time provided, and expect to provide in the future, investment banking, commercial banking and other financial transactions with us and
our affiliates, for which they have received and may continue to receive customary fees and commissions. Affiliates of the underwriters are lenders under our May 2007 term loan and bridge loan
facility, for which they receive customary fees, and may receive a portion of amounts to be repaid under our May 2007 bridge credit loan facility from the proceeds of this offering. See “Use of
Proceeds.” Because more than 10% of the net proceeds of this offering may be received by National Association of Securities Dealers, Inc., or NASD, members participating in the offering or their
affiliates or associated persons, this offering will be conducted in accordance with NASD Conduct Rule 2710(h). European Economic Area In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a Relevant Member State), each underwriter has represented and agreed
that with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State (the Relevant Implementation Date) it has not made and will not make an
offer of notes to the public in that Relevant Member State prior to the publication of a prospectus in relation to the notes which has been approved by the competent authority in that Relevant Member
State or, where appropriate, approved in another Relevant Member State and notified to the competent authority in that Relevant Member State, all in accordance with the Prospectus Directive, except
that it may, with effect from and including the Relevant Implementation Date, make an offer of notes to the public in that Relevant Member State at any time: (a) to legal entities which are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities; (b) to any legal entity which has two or more of (1) an average of at least 250 employees during the last financial year; (2) a total balance sheet of more than €43,000,000 and (3) an annual
net turnover of more than €50,000,000, as shown in its last annual or consolidated accounts; or (c) in any other circumstances which do not require the publication by the Issuer of a prospectus pursuant to Article 3 of the Prospectus Directive. For the purposes of this provision, the expression an “offer of notes to the public” in relation to any notes in any Relevant Member State means the communication in any form and by any
means of sufficient information on the terms of the offer and the notes to be offered so as to enable an investor to decide to purchase or subscribe the notes, as the same may be varied in that
Member State by any measure implementing the Prospectus Directive in that Member State and the S-49
expression Prospectus Directive means Directive 2003/71/EC and includes any relevant implementing measure in each Relevant Member State. United Kingdom Each underwriter has represented and agreed that it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement
to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of the notes in circumstances in which Section
21(1) of such Act does not apply to us and it has complied and will comply with all applicable provisions of such Act with respect to anything done by it in relation to any notes in, from or
otherwise involving the United Kingdom. Certain legal matters in connection with the notes offered hereby will be passed upon for us by Leo C. Farrenkopf, Vice President and Assistant General Counsel of Quest Diagnostics, and by
Shearman & Sterling LLP, New York, New York. Certain legal matters in connection with the notes offered hereby will be passed upon for the underwriters by Fried, Frank, Harris, Shriver & Jacobson
LLP, New York, New York. The consolidated statements and management’s assessment of the effectiveness of internal control over financial reporting of Quest Diagnostics (which is included in Management’s Report on
Internal Control over Financial Reporting) incorporated in this prospectus supplement by reference to Quest Diagnostics’ Annual Report on Form 10-K for the year ended December 31, 2006, have
been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and
accounting. The consolidated financial statements of AmeriPath, Inc. incorporated by reference in this prospectus supplement for the year ended December 31, 2006 have been audited by Ernst & Young LLP,
independent auditors, as set forth in their report thereon incorporated by reference herein. Such consolidated financial statements are incorporated herein by reference in reliance upon such report
given on the authority of such firm as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION We file annual, quarterly and special reports, proxy statements and other information with the Securities and Exchange Commission, or the SEC. You may read and copy any reports, statements
or other information we file with the SEC at its public reference rooms at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public
reference rooms. Our filings are also available to the public on the Internet, through a database maintained by the SEC at http://www.sec.gov. In addition, you can inspect and copy our reports, proxy
statements and other information at the offices of the New York Stock Exchange, Inc., 20 Broad Street, New York, New York 10005. Our subsidiary guarantors do not file separate financial statements with the SEC and do not independently publish their financial statements. Instead, our subsidiary guarantors’ financial
condition, results of operations and cash flows are consolidated into our financial statements. Summarized financial information illustrating our subsidiary guarantors’ financial condition, results of
operations and cash flows, on a combined basis, is disclosed in the notes to our consolidated financial statements which are incorporated by reference into this prospectus supplement, as noted below. The SEC allows us to incorporate by reference into this document the information we filed with it. This means that we can disclose important business, financial and other information to you by S-50
referring you to other documents separately filed with the SEC. All information incorporated by reference is part of this document, unless and until that information is updated and superseded by the
information contained in this document or any information incorporated later. We incorporate by reference the documents listed below:
Our current reports on Form 8-K, filed February 5, 2007, February 16, 2007, April 2, 2007, April 16, 2007, April 19, 2007, May 22, 2007, May 31, 2007, June 6, 2007 and June 14, 2007; 2. Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007; 3. Our Annual Report on Form 10-K for the fiscal year ended December 31, 2006; 4. “Item 8. Financial Statements and Supplementary Data; Index to Consolidated Financial Statements” in the Annual Report on Form 10-K of AmeriPath, Inc., for the fiscal year ended
December 31, 2006; and 5. “Item 1. Financial Statements” in the Quarterly Report on Form 10-Q of AmeriPath, Inc., for the quarter ended March 31, 2007. Our filings with the SEC, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K and amendments to those reports, are available free of
charge on our website as soon as reasonably practicable after they are filed with, or furnished to, the SEC. Our internet website is located at http://www.questdiagnostics.com. The contents of the
website are not incorporated by reference into this prospectus. You also may request a copy of these filings, at no cost, by writing or telephoning our Investor Relations Department at the following
address: Quest Diagnostics Incorporated We also incorporate by reference all future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934 prior to the termination of the offering
made hereby. You should rely only on the information contained or incorporated by reference in this prospectus supplement. We have not authorized any other person to provide you with different
information. If anyone provides you with different or inconsistent information you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where the offer and sale
is not permitted. You should assume that the information appearing in this prospectus supplement and information incorporated by reference into this prospectus supplement is accurate only as of the
date of the documents containing the information. Our business, financial condition, cash flows, results of operation and prospects may have changed since that date. S-51
1.
1290 Wall Street West
Lyndhurst, New Jersey 07071
Attention: Investor Relations
(201) 393-5000
(This Page Intentionally Left Blank)
SUBJECT TO COMPLETION, DATED JUNE 19, 2007 QUEST DIAGNOSTICS INCORPORATED Debt Securities We may offer and sell, from time to time, in one or more offerings, the debt securities we describe in this prospectus, for sale directly to purchasers or through underwriters, dealers or agents to
be designated at a future date. Our debt securities may be fully and unconditionally guaranteed on an unsecured basis by our subsidiaries. We will provide the specific terms of these debt securities in supplements or term sheets to this prospectus. We urge you to read carefully this prospectus, the accompanying prospectus
supplements and term sheets, which will describe the specific terms of the securities offered, before you make your investment decision. Investing in our debt securities involves risks that are described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission or in the applicable
prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense. The date of this prospectus is June 19, 2007
Guarantees of Debt Securities
TABLE OF CONTENTS
Page
ii
ii
iii
1
3
4
5 Description of Senior Debt Securities and Guarantees of Senior Debt Securities
6
7
8
8 i
The information contained in this prospectus is not complete and may be changed. You should rely only on the information provided in or incorporated by reference in this prospectus, any
prospectus supplement, any pricing supplement or documents to which we otherwise refer you. We have not authorized anyone else to provide you with different information. We are not making an
offer of any securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus, any prospectus supplement or any document incorporated by
reference is accurate as of any date other than the date of the document in which such information is contained or such other date referred to in such document, regardless of the time of any sale or
issuance of a security. This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”) using a “shelf” registration process. This prospectus provides you with
a general description of the securities we may offer. Each time we sell or issue securities, we will provide a prospectus supplement and, if applicable, a pricing supplement, that will contain specific
information about the terms of that specific offering of securities and the specific manner in which they may be offered. The prospectus supplement and any applicable pricing supplement may also
add to, update or change any of the information contained in this prospectus. The prospectus supplement and any applicable pricing supplement may also contain information about any material U.S.
federal income tax considerations relating to the securities described in the prospectus supplement. You should read both this prospectus, the applicable prospectus supplement and any applicable
pricing supplement, together with the additional information described under “Where You Can Find More Information.” You should read the entire prospectus and the applicable prospectus
supplement, including the information incorporated by reference, before making an investment decision. As used in this prospectus, the terms “Quest Diagnostics,” “we,” “us” and “our” refer to
Quest Diagnostics Incorporated and its consolidated subsidiaries, unless the context clearly indicates otherwise. This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual document for complete information. All of the
summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed or will be filed or incorporated by reference as exhibits to the
registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under “Where You Can Find More Information.” The registration statement that contains this prospectus (including the exhibits to the registration statement) contains additional information about us and the securities offered under this
prospectus. That registration statement can be read at the SEC web site (www.sec.gov) or at the SEC offices mentioned under the heading “Where You Can Find More Information.” QUEST DIAGNOSTICS INCORPORATED The Company We are the nation’s leading provider of diagnostic testing, information and services, providing insights that enable physicians and other healthcare professionals to make decisions to improve
health. We offer patients and physicians the broadest access to diagnostic laboratory services through our nationwide network of laboratories and our own patient service centers. We provide
interpretive consultation through the largest medical and scientific staff in the industry, with approximately 900 M.D.’s and Ph.D.’s around the country. We are the leading provider of esoteric testing,
including gene-based testing, the leading provider of anatomic pathology services, including dermatopathology, and the leading provider of testing for drugs of abuse. We are also a leading provider of
testing for clinical trials and risk assessment services for the life insurance industry. We empower healthcare organizations and clinicians with state-of-the-art information technology solutions that can
improve patient care and medical practice. During 2006, we generated net revenues of $6.3 billion and processed approximately 151 million requisitions for testing. Each requisition form accompanies a patient specimen, indicating the tests to ii
be performed and the party to be billed for the tests. Our customers include patients, physicians, hospitals, employers, governmental institutions and other commercial clinical laboratories. On May 31,
2007, we acquired AmeriPath Group Holdings, Inc., the ultimate parent of AmeriPath, Inc., which generated net revenues of $752 million during 2006. We operate a nationwide network of greater than 2,100 of our own patient service centers, principal clinical laboratories located in more than 30 major metropolitan areas throughout the United
States and approximately 150 smaller “rapid response” laboratories (including, in each case, facilities operated at our joint ventures). We provide full esoteric testing services, including gene-based
testing, on both coasts through our Quest Diagnostics Nichols Institute laboratory facilities, located in San Juan Capistrano, California and Chantilly, Virginia, and through our Specialty Laboratories
facility located in Valencia, California, as well as infectious and immunologic disease testing through our Focus Diagnostics laboratory facility, located in Cypress, California. Our AmeriPath subsidiary
operates 40 outpatient anatomic pathology laboratories and provides inpatient anatomic pathology and medical director services for approximately 200 hospitals throughout the country. We also have
laboratory facilities in Mexico City, Mexico, San Juan, Puerto Rico and Heston, England. We are a Delaware corporation. We are the successor to MetPath Inc., a New York corporation that was organized in 1967. From 1982 to 1996, we were a subsidiary of Corning Incorporated, or
Corning. On December 31, 1996, Corning distributed all of the outstanding shares of our common stock to the stockholders of Corning. In August 1999, we completed the acquisition of SmithKline
Beecham Clinical Laboratories, Inc., or SBCL, which operated the clinical laboratory business of SmithKline Beecham plc, or SmithKline Beecham. Our principal executive offices are located at 1290 Wall Street West, Lyndhurst, New Jersey 07071, telephone number: (201) 393-5000. WHERE YOU CAN FIND MORE INFORMATION We file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information we file with the SEC at
its public reference rooms at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference rooms. Our filings are also available
to the public on the Internet, through a database maintained by the SEC at http://www.sec.gov. In addition, you can inspect and copy our reports, proxy statements and other information at the
offices of the New York Stock Exchange, Inc., 20 Broad Street, New York, New York 10005. Our subsidiary guarantors do not file separate financial statements with the SEC and do not independently publish their financial statements. Instead, our subsidiary guarantors’ financial
condition, results of operations and cash flows are consolidated into our financial statements. Summarized financial information illustrating our subsidiary guarantors’ financial condition, results of
operations and cash flows, on a combined basis, is disclosed in the notes to our consolidated financial statements which are incorporated by reference into this prospectus, as noted below. The
summarized financial information does not include the subsidiaries recently acquired in our acquisition of AmeriPath Group Holdings, Inc. The SEC allows us to incorporate by reference into this document the information we filed with it. This means that we can disclose important business, financial and other information to you by
referring you to other documents separately filed with the SEC. All information incorporated by reference is part of this document, unless and until that information is updated and superseded by the
information contained in this document or any information incorporated later. We incorporate by reference the documents listed below:
1.
Our current reports on Form 8-K, filed February 5, 2007, February 16, 2007, April 2, 2007, April 16, 2007, April 19, 2007, May 22, 2007, May 31, 2007, June 6, 2007 and June 14, 2007; 2. Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007; 3. Our Annual Report on Form 10-K for the fiscal year ended December 31, 2006; iii
4. “Item 8. Financial Statements and Supplementary Data; Index to Consolidated Financial Statements” in the Annual Report on Form 10-K of AmeriPath, Inc., for the fiscal year ended
December 31, 2006; and 5. “Item 1. Financial Statements” in the Quarterly Report on Form 10-Q of AmeriPath, Inc., for the quarter ended March 31, 2007. Our filings with the SEC, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K and amendments to those reports, are available free of
charge on our website as soon as reasonably practicable after they are filed with, or furnished to, the SEC. Our internet website is located at http://www.questdiagnostics.com. The contents of the
website are not incorporated by reference into this prospectus. You also may request a copy of these filings, at no cost, by writing or telephoning our Investor Relations Department at the following
address: Quest Diagnostics Incorporated We also incorporate by reference all future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities and Exchange Act of 1934 prior to the termination of the
offering made hereby. iv
1290 Wall Street West
Lyndhurst, New Jersey 07071
Attention: Investor Relations
(201) 393-5000
Some statements and disclosures in this prospectus, or any accompanying prospectus supplement and the documents incorporated herein or therein by reference are forward-looking statements.
Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could
significantly cause our plans and expectations, including actual results, to differ materially from the forward-looking statements. The Private Securities Litigation Reform Act of 1995, or the Litigation
Reform Act, provides a “safe harbor” for forward-looking statements to encourage companies to provide prospective information about their companies without fear of litigation. We would like to take advantage of the “safe harbor” provisions of the Litigation Reform Act in connection with the forward-looking statements included or incorporated by reference in this
document. Investors are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented or incorporated by reference in this document. The following
important factors could cause our actual financial results to differ materially from those projected, forecasted or estimated by us in forward-looking statements: (a) Heightened competition, including increased pricing pressure, competition from hospitals, and competition from physicians. (b) Impact of changes in payer mix, including any shift from fee-for-service to capitated fee arrangements. (c) Adverse actions by government or other third-party payers, including unilateral reduction of fee schedules payable to us, competitive bidding, an increase in the practice of negotiating for
exclusive arrangements that involve aggressively priced capitated or fee for service payments by healthcare insurers or other payers and threats by third-party payers against physicians and
patients that effectively eliminate their choice to use an out-of-network provider under preferred provider organization and similar plans. (d) The impact upon our testing volume and collected revenue or general or administrative expenses resulting from our compliance with Medicare and Medicaid administrative policies and
requirements of third-party payers. These include: (1) the requirements of Medicare carriers to provide diagnosis codes for many commonly ordered tests and the possibility that third-party payers will increasingly adopt similar
requirements; (2) the policy of the Centers for Medicare and Medicaid Services to limit Medicare reimbursement for tests contained in automated chemistry panels to the amount that would have been
paid if only the covered tests, determined on the basis of demonstrable “medical necessity,” had been ordered; (3) continued inconsistent practices among the different local carriers administering Medicare; (4) inability to obtain from patients an advance beneficiary notice form for tests that cannot be billed without prior receipt of the form; (5) the potential need to monitor charges and lower certain fees to Medicare to comply with the Office of the Inspector General’s proposed rule pertaining to exclusion of providers for
submitting claims to Medicare containing charges that are substantially in excess of the provider’s usual charges; and (6) increased challenges in operating as a non-contracted provider with respect to healthcare insurers. (e) Adverse results from pending or future government investigations, lawsuits or private actions. These include, in particular, significant monetary damages, loss or suspension of 1
licenses, and/or suspension or exclusion from the Medicare and Medicaid programs and/or criminal penalties. (f) Failure to efficiently integrate acquired businesses and to manage the costs related to any such integration, or to retain key technical, medical and management personnel. (g) Inability to obtain professional liability or other insurance coverage or a material increase in premiums for such coverage or reserves for self-insurance. (h) Denial of certification under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, or denial of other licenses for any of our clinical laboratories under the CLIA
standards, revocation or suspension of the right to bill the Medicare and Medicaid programs or other adverse regulatory actions by federal, state and local agencies. (i) Changes in federal, state or local laws or regulations, including changes that result in new or increased federal or state regulation of commercial clinical laboratories, including regulation
by the Food and Drug Administration. (j) Inability to achieve expected benefits from our acquisitions of other businesses. (k) Inability to achieve additional benefits from our Six Sigma and standardization initiatives. (l) Adverse publicity and news coverage about the clinical laboratory industry or us. (m) Computer or other IT system failures that affect our ability to perform tests, report test results or properly bill customers, including potential failures resulting from the standardization of
our IT systems and other system conversions, telecommunications failures, malicious human acts (such as electronic break-ins or computer viruses) or natural disasters. (n) Development of technologies that substantially alter the practice of laboratory medicine, including technology changes that lead to the development of more cost-effective tests such as (1)
point-of-care tests that can be performed by physicians in their offices, (2) esoteric tests that can be performed by hospitals in their own laboratories or (3) home testing that can be carried out
without requiring the services of clinical laboratories. (o) Issuance of patents or other property rights to our competitors or others that could prevent, limit or interfere with our ability to develop, perform or sell our tests or operate our
business. (p) Development of tests by our competitors or others which we may not be able to license, or usage of our technology or similar technologies or our trade secrets by competitors, any of
which could negatively affect our competitive position. (q) Regulatory delay or inability to commercialize newly licensed tests or technologies or to obtain appropriate reimbursements for such tests. (r) Inability to obtain or maintain adequate patent and other proprietary rights protections of our products and services or to successfully enforce our proprietary rights. (s) Impact of any national healthcare information network and the adoption of standards for health information technology interoperability that are incompatible with existing software and
hardware infrastructure requiring widespread replacement of systems and/or software. (t) The impact of the privacy regulations, security regulations and standards for electronic transactions regulations issued under the Health Insurance Portability and Accountability Act of
1996 and any applicable state laws or regulations. (u) Inability to promptly or properly bill for our services or to obtain appropriate payments for services that we do bill. (v) Changes in interest rates and changes in our credit ratings from Standard & Poor’s Rating Services and Moody’s Investor Services causing an unfavorable impact on our cost of and access
to capital. (w) Inability to hire and retain qualified personnel or the loss of the services of one or more of our key senior management personnel. (x) Terrorist and other criminal activities, hurricanes, earthquakes or other natural disasters, which could affect our customers, transportation or systems, or our facilities, and for which
insurance may not adequately reimburse us. 2
Except as may be described otherwise in a prospectus supplement or pricing supplement, we will add the net proceeds from the sale of the securities under this prospectus to our general funds
and will use them for general corporate purposes, which may include, among other things, funding acquisitions or reducing or refinancing indebtedness. 3
RATIO OF EARNINGS TO FIXED CHARGES Set forth below is information concerning the historical ratio of earnings to fixed charges for Quest Diagnostics. This ratio shows the extent to which our business generates enough earnings after
the payment of all expenses other than interest to make required interest payments on our debt. For this purpose, earnings consist of pretax income from continuing operations plus fixed charges. Fixed charges consist of interest expense and one-third of rental expense, representing that
portion of rental expense we deemed representative of an appropriate interest factor.
Three Months
Year Ended December 31,
2007
2006
2005
2004
2003
2002 Ratio of earnings to fixed charges
5.4x
8.2x
9.9x
9.2x
8.4x
7.2x 4
Ended March 31,
Overview This prospectus is part of a registration statement that we filed with the SEC utilizing a “shelf” registration process. Under this shelf process, we may sell our senior debt securities, or guarantees
of our debt securities, in one or more offerings. The terms of the securities will be determined at the time of offering. We will refer to the debt securities and the guarantees of the debt securities or any combination of those securities, proposed to be sold under this prospectus and the applicable prospectus
supplement or pricing supplement as the “securities.” Because we are a well-known seasoned issuer, as defined in Rule 405 of the Securities Act of 1933, as amended, we may add to and offer additional securities including secondary securities and
guarantees of securities by filing a prospectus supplement or term sheet with the SEC at the time of the offer. Prospectus Supplement or Pricing Supplement This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a prospectus supplement or pricing supplement that will
contain specific information about the terms of that offering. The prospectus supplement or pricing supplement may also add to or change information contained in this prospectus. If so, the
prospectus supplement or pricing supplement should be read as superseding this prospectus. You should read both this prospectus and any prospectus supplement or pricing supplement together with
additional information described under the heading “Where You Can Find More Information.” The prospectus supplement or pricing supplement to be provided with this prospectus will describe the terms of any securities that we offer and any initial offering price to the public in that
offering, the purchase price and net proceeds that we will receive and the other specific terms related to our offering of the securities. For more details on the terms of the securities, you should read
the exhibits filed with or incorporated by reference in our registration statement, of which this prospectus is a part. 5
DESCRIPTION OF SENIOR DEBT SECURITIES We may issue senior debt securities from time to time in one or more distinct series. We may also issue guarantees of our senior debt securities from time to time. As required by U.S. federal law for all bonds and notes of companies that are publicly offered, the senior debt securities will be governed by a document called an “indenture.” An indenture is a
contract between us and a financial institution, in this case, The Bank of New York, acting as trustee on your behalf, or other trustee we may select. The indenture will be subject to and governed by
the Trust Indenture Act of 1939. We have filed the indenture as an exhibit to our Securities Act filings and Exchange Act reports that we have filed with the SEC. See “Where You Can Find More Information” for information
on how to obtain a copy of the indenture. The senior debt securities will be issued under an indenture dated as of June 27, 2001 as supplemented by a first supplemental indenture, dated as of June 27, 2001, each among Quest
Diagnostics, as issuer, the Initial Subsidiary Guarantors, as guarantors, and The Bank of New York, as trustee, as further supplemented by a second supplemental indenture, dated as of November 26,
2001, among Quest Diagnostics, the Subsidiary Guarantors and The Bank of New York, as further supplemented by a third supplemental indenture, dated as of April 4, 2002, among Quest
Diagnostics, the additional Subsidiary Guarantors and The Bank of New York, as further supplemented by a fourth supplemental indenture, dated as of March 19, 2003, among Quest Diagnostics, the
additional Subsidiary Guarantors and The Bank of New York, as further supplemented by a fifth supplemental indenture, dated as of April 16, 2004, among Quest Diagnostics, the additional
Subsidiary Guarantors and The Bank of New York, as further supplemented by a sixth supplemental indenture, dated as of October 31, 2005, among Quest Diagnostics, the additional Subsidiary
Guarantors and The Bank of New York, as further supplemented by a seventh supplemental indenture, dated as of November 21, 2005, among Quest Diagnostics, the additional Subsidiary
Guarantors and The Bank of New York and as further supplemented by an eighth supplemental indenture, dated as of July 31, 2006, among Quest Diagnostics, the additional Subsidiary Guarantors
and The Bank of New York and as further supplemented by the ninth supplemental indenture dated September 30, 2006, among Quest Diagnostics, the additional Subsidiary Guarantors and The
Bank of New York (collectively, the “Indenture”). The Indenture for the senior debt securities may also be modified by future supplemental indentures. The terms of the senior debt securities include
those stated in the Indenture and those made part of the Indenture by reference to the Trust Indenture Act of 1939. A copy of the Indenture is available for inspection at the office of the trustee. 6
AND GUARANTEES OF SENIOR DEBT SECURITIES
We may sell the securities to or through agents or underwriters or directly to one or more purchasers. By Agents We may use agents to sell the securities. The agents will agree to use their reasonable best efforts to solicit purchases of the period of their appointment. By Underwriters We may sell the securities to underwriters. The underwriters may resell the securities in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying
prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to certain conditions. Each underwriter will be obligated to purchase all the
securities allocated to it under the underwriting agreement. The underwriters may change any initial public offering price and any discounts or concessions they give to dealers. Direct Sales We may sell securities directly to investors. In this case, no underwriters or agents would be involved. As one of the means of direct issuance of securities, we may utilize the services of any available electronic auction system to conduct an electronic “dutch auction” of the offered securities among
potential purchasers who are eligible to participate in the auction of those offered securities, if so described in the prospectus supplement or pricing supplement. General Information Any underwriters or agents will be identified and their compensation described in a prospectus supplement or pricing supplement. We may have agreements with the underwriters, dealers and agents to indemnify them against certain civil liabilities, including liabilities under the Securities Act or to contribute to payments
they may be required to make. Underwriters, dealers and agents may engage in transactions with, or perform services for, us or our subsidiaries in the ordinary course of their business. 7
The validity of any securities issued hereunder will be passed upon for our company by Shearman & Sterling LLP, New York, New York. The consolidated financial statements and management’s assessment of the effectiveness of internal control over financial reporting of Quest Diagnostics (which is included in Management’s
Report on Internal Control over Financial Reporting) incorporated in this prospectus by reference to Quest Diagnostics’ Annual Report on Form 10-K for the year ended December 31, 2006, have
been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and
accounting. The consolidated financial statements of AmeriPath, Inc. incorporated by reference in this prospectus and registration statement for the year ended December 31, 2006 have been audited by
Ernst & Young LLP, independent auditors, as set forth in their report thereon incorporated by reference herein. Such consolidated financial statements are incorporated herein by reference in reliance
upon such report given on the authority of such firm as experts in accounting and auditing. 8
$800,000,000 $375,000,000 6.40% Senior Notes due 2017 PROSPECTUS SUPPLEMENT
MORGAN STANLEY
Barclays Capital
$425,000,000 6.95% Senior Notes due 2037
June 19, 2007